Time Interval	VN-NP Telemedicine Algorithm (mean and standard deviation, minutes)

Onset to Door	32.3 ± 20.5

Onset to Call	42.8 ± 21.2

Onset to Lab	110.5 ± 12.0

Onset to Decision	112.6 ± 31.1

Onset to rt-PA	159.0 ± 8.5

Door to Call	19.6 ± 18.7

Door to Consent	39.8 ± 26.0

Door to Lab	75.0 ± 32.4

Door to Neuro Exam	54.2 ± 15.1

Door to CT Reading	78.2 ± 23.4

Door to Decision	69.6 ± 9.6

Call to Consent	21.0 ± 10.8

Call to Neuro Exam	31.5 ± 11.5

Call to Decision	53.2 ± 9.0

Consent to Neuro Exam	9.0 ± 16.8

Consent to Decision	30.7 ± 19.3

Consent to rt-PA	67.0 ± 30.5

Decision to rt-PA	45.5 ± 21.9


				SED	Significance

	Year 1	Year 2	Year 3	Treatment	Year	Treatment	Year	Interaction

Livera

 Treated

No.b	11/15	4/14	2/12

Concentration	7.45 (56)	4.36 (19)	— (45)	1.67	1.58	NS	*	NS

 Control

No.	13/14	7/19	2/16

Concentration	10.57 (112)	7.30 (53)	— (265)

Kidney fat

 Treated

No.	1/15	0/14	2/12

Concentration	— (45)	— (ND)	— (134)

 Control

No.	6/15	3/18	3/16

Concentration	— (77)	— (96)	— (29)

Musclea

 Treated

No.	0/15	10/13	9/12

Concentration	— (ND)	14.83 (220)	31.76 (1,009)	3.78	3.78	*	NS	#

 Control

No.	0/15	19/19	11/15

Concentration	— (ND)	42.8 (1,832)	26.3 (692)


Parasite forms	IC50 (μM)	Time (h)	SI

Epimastigotes (Y strain)	255.15 ± 32.6	24	>15

Metacyclic trypomastigotes (Dm28c)	191.8 ± 10.5	24	>21

Bloodstream trypomastigotes (Y strain)	259.4 ± 6.1	24	>16

Intracellular amastigotes (Y strain)	188.2 ± 47.5	48	>21


Algorithm for feature selection	Average sensitivity for 5-fold cross validation (%)	Average specificity for 5-fold cross validation (%)

FDAFSA	84	86

RTPFSGA	94	59

PromoBot[FDAFSA + RTPFSGA]	89	86


Factors	Criteria	Comment

Sea level height in tsunami, tide level in storm surge, flood level	>2.5 m	Unsuitable

2.5–1.5 m	Neutral

<1.5 m	Suitable

Geological environment	Geologically inappropriate areas and near-fault region	Unsuitable

Others	Suitable

Distance from gas stations, natural gas fueling stations, high voltage lines, and power plants	<50 m	Unsuitable

50–100 m	Neutral

>100 m	Suitable

Distance from dangerous goods warehouse	<500 m	Unsuitable

500–1000 m	Neutral

>1000 m	Suitable

Distance from high pressure gas pipelines	<25 m	Unsuitable

25–50 m	Neutral

>50 m	Suitable

Terrain slope	>30°	Unsuitable

15–30°	Neutral

>15°	Suitable

Distance from waters	0–30 m	Neutral

>30 m	Suitable

Terrain elevation	<1.5 m	Neutral

>1.5 m	Suitable

Distance from heritage conservation areas	0–30 m	Neutral

>30 m	Suitable

Distance from waste treatment stations	<100 m	Neutral

>100 m	Suitable


Clinical trial	Median age	Range	≥75 years	PS 2	Visceral metastases

TROPIC	68	62–73	18%	7%	25%

COU-AA-301	69	42–95	28%	10%	11% (liver metastases)

AFFIRM	69	41–92	25%	8.5%	23.2%


	n: 78	%

Working status at the time of admission	Yes	68	87.2

No	10	12.8

Sector of work	Industry	17	21.8

Service	61	78.2

Total duration of work (month) Mean ±SD (min - max)	34.6±51 (1-156)


Season	Response	Predictor variables	θ	SE	P-value

Dry	Frequency of occurrence	Distance to permanent water	-2.49E-04	1.11E-04	<0.05

		(Distance to permanent water)2	4.67E-08	2.18E-08	<0.05

		Distance to rangerpost/lodge	1.66E-05	9.30E-06	<0.1

		Wooded grassland	2.31E-01	1.18E-01	<0.1

Dry	Average biomass	Distance to rangerpost/lodge	-7.91E-05	1.79E-05	<0.0001

Wet	Frequency of occurrence	Distance to water	5.04E-04	2.02E-04	<0.05

		(Distance to water)2	-3.42E-07	1.10E-07	<0.01

		Distance to rangerpost/lodge	-5.44E-05	7.88E-06	<0.0001

		Wooded grassland	-1.60E-01	9.81E-02	<0.2

		Dense woodland	-4.61E-01	2.05E-01	<0.05

Wet	Average biomass	Distance to rangerpost/lodge	-5.18E-05	1.77E-05	<0.01

		Open grassland	1.37E + 00	2.16E-01	<0.0001

		Open woodland	1.60E + 00	4.23E-01	<0.001


Type of samples collected	Personal breathing zone mass concentrations (μg/m3)	Study

Estimated inhalable mass	0.7 - 53	Maynard et al. 2004 [21]

Total gravimetric mass	N.D. - 331.7	Han et al. 2008 [19]

Total gravimetric mass	7.8 - 320.8	Lee et al. 2010 [20]

Total carbon-inhalable size fraction	64-1094	Methner et al. 2010 [25]

Elemental carbon- inhalable size fraction	N.D. - 38	Methner et al. 2012 [24]

Elemental carbon- inhalable size fraction	N.D. - 7.86	Dahm et al. 2012 [23]

Elemental carbon- respirable size fraction	45 - 80	Birch et al. 2011 [22]


		Culture (MGIT + LJ)

		Positive	Negative	Total

Magnetic bead FM (with blinded re-checking of discrepants)

	Positive	76	12	88

	Negative	31	163	194

	Total	107	175	282

Sensitivity, %(95% CI)	71.0%(61.5 - 79.4)

Specificity, %(95% CI)	93.1%(88.3 - 96.4)

Overall accuracy, %(95% CI)	84.8%(80.0-88.7)

PPV, %(95% CI)	86.4%(77.4-92.8)

NPV, %(95% CI)	84.0%(80.0-88.7)


	Adjusted odds of treatment success (cure/completed) vs. failure/relapse(N = 1,302)OR (95% CI)	Adjusted odds of treatment success (cure/completed) vs. failure/relapse/death(N = 1,483)OR (95% CI)	Adjusted odds of treatment success (cure/completed) vs. failure/relapse/death/lost to follow-up(N = 1,864)OR (95% CI)

HIV

 No	1.7 (0.9; 3.4)	2.7 (1.7; 4.2)	2.3 (1.6; 3.4)

 Yes	Reference	Reference	Reference

Regimen

 Standardized	2.7 (1.8; 3.9)	1.4 (1.1; 1.9)	1.0 (0.8; 1.3)

 Individualized	Reference	Reference	Reference

First DR-TB episode

 Yes	8.8 (5.7; 13.5)	5.4 (3.8; 7.7)	2.1 (1.1; 4.1)

 No	Reference	Reference	Reference

AFB positive

 No	4.2 (2.1; 8.2)	2.1 (1.4; 3.1)	2.1 (1.5; 2.8)

 Yes	Reference	Reference	Reference

Bilateral disease	–

 No		1.4 (1.1.; 1.9)	1.3 (1.1; 1.6)

 Yes		Reference	Reference

Number of previous regimens	–	–	0.4 (0.2; 0.7)

Diabetes	–	–

 No/Unknown			0.7 (0.5; 0.9)

 Yes			Reference

Macro-region			–

 North	0.9 (0.3; 2.2)	0.9 (0.5; 1.5)	–

 Northeastern	0.2 (0.1; 0.5)	0.4 (0.4; 0.7)

 Centre-West	0.4 (0.1; 1.8)	1.0 (0.4; 2.6)

 Southeastern	0.4 (0.2; 0.8)	0.7 (0.5; 1.1)

 South	Reference	Reference


Universe	Registered users of the private area of Company XX’s website who had used this service at least once

Sampling procedure	By means of a structured survey accessed online

Sample	23,223

Scope	Spain

Real sample	4,178

Sampling error	±1.05%

Level of confidence	95% (Z = 1.96)

Maximum variance allowed	P = q = 50%

Fieldwork	June/July 2016


GA at delivery	Stillborn	Live born

n	%	n	%

<37 weeks	17	85	27	82

37–42 weeks	3	15	5	15

>42 weeks	0	0	1	3


Sensor Response	Body Movement

	Abnormal	Normal

Detection	48	3

No detection	0	45


Characteristic	Percent

Race

 White	15

 African American	85

Maternal smoking at time of pregnancy

 No	44

 Yes	56

Breast-fed

 Yes	6

 No	94

No. of older siblings

 0	25

 1	25

 ≥ 2	50

Maternal height (cm)

 144–155.9	29

 156–165.9	54

 166–181	17

Maternal prepregnancy BMI (kg/m2)

 16–19.9	21

 20–24.9	47

 25–29.9	23

 30–44	9

Maternal age at menarche (years)

 8–11	21

 12	29

 13	25

 ≥ 14	26

Maternal age at enrollment in CPP (years)

 13–19	23

 20–24	36

 25–29	23

 30–42	18

Family SEI at time of pregnancy

 0–2.5	17

 2.6–5.0	59

 ≥ 5.1	24


	Suicidal ideation	Depressive symptoms	Loneliness

	B	SE	β	B	SE	β	B	SE	β

STEP 1

Size of the discrepancy	0.03	0.01	0.35**	0.35	0.13	0.26**	0.09	0.14	0.06

Direction of the discrepancy	0.03	0.01	0.22*	0.65	0.19	0.33**	0.43	0.20	0.21*

STEP 2

Size of the discrepancy*	0.04	0.02	0.53*	0.75	0.27	0.59**	0.79	0.29	0.61**

Direction of the discrepancy


Raman reporter	λmax (nm)	λ0(nm)	Reference

Carboxyfluorescein (FAM)	494	514.5	[85]

Rhodamine 6 G (R6G)	524	514.5, 532	[85–88]

TRITC-DHPE	540	514.5	[89]

Carboxy-X-rhodamine (ROX)	585	514.5, 632.8	[85]

BIODIPY TR-X	588	632.8	[85]

Crystal violet (CV)	590	514.5, 647.1	[86, 90]

Malachite green (MG)	618	632.8	[91]

Malachite green isothiocyanate (MGITC)	625	632.8	[91]

Methylene blue 	570–760∤	785	[92, 93]

Cy5.5	683	632.8	[85]

3,3′-diethylthiatricarbocyanine iodide (DTTC)	765	785	[94]


Relationship to patient	N (%)i

Wife/partner	444 (86.4)

Other relative	13 (2.2)

Friend	2 (0.3)

Other	22 (3.7)

Age (years)

< 54	68 (11.4)

55-64	190 (31.9)

65-74	225 (37.8)

75+	96 (16.1)

Overall health

Very good	154 (25.9)

Good	280 (47.1)

Fair	118 (19.8)

Poor	18 (3.0)

Very poor	5 (0.8)

Ethnicity

White British/Irish	562 (94.5)

South Asian	3 (0.5)

African/Caribbean	5 (0.8)

Other	0 (0)

Current situation

Employed	136 (22.9)

Retired	388 (65.2)

Other	35 (5.9)

Current or most recent occupation

Professional	136 (22.9)

Managerial	51 (8.6)

Clerical	164 (27.6)

Technical/craft	7 (1.2)

Manual/service	82 (13.8)


	Methods	Negative effects	Number of published papers (PubMed 1975–2015)

In vivo human studies	Biomonitoring methodsCorrelation studiesCross-sectional studiesPlasma/urine determinations (ELISA, GC/MS,HPLC, LC/MS)	General toxicityReproduction and developmentNeurodevelopment and neuroendocrine systemImmune systemCardiovascular systemMetabolism (diabetes, weight gain, obesity)GenotoxicityCarcinogenicity	442

In vivo animal studies (mice, rats, monkeys)	Prenatal exposureNeonatal exposureAdult animals	Immune systemMetabolism (glucose intolerance, hyper- insulinaemia, diabetes, weight gain, hyper- tryglyceridemia)CancerReproduction and development	565


Characteristic	n	%

Sex

Female	1150	48.4

Male	1078	54.6

Age

≤15	572	26.8

16	593	27.8

17	457	21.4

≥18	514	24.1

Grade

9-10	1299	60.4

11-12	851	39.5

Income per capita (Euros)

Lowest (0–200 TL) (0–97 Euros)	479	30.7

Lowest middle (201–400 TL) (98–193 Euros)	555	35.6

Upper middle (401–600 TL) (194–290 Euros)	216	13.8

Highest (601 TL +) (291 Euros and over)	311	19.9

Social class

Blue collar/Unemployed	956	46.9

Self Employed	444	21.8

Employer	170	8.3

White collar/Manager	468	23.0

Mother’s Education

Illiterate/Only literate	139	6.4

Primary (5 years)	908	41.7

Secondary (8 years)	370	17.0

High school (11 years)	426	19.6

University (13+ years)	332	15.3

School Type

Trade high school	285	13.3

Technical high school for girls	212	9.9

Standard high school	558	26.0

Industrial technical high school	489	22.7

Anatolian/Science/Private high school	606	28.2

Mobile phone utilization

Yes	2005	92.0

No	175	8.0


Document type	Diagnosis	Signs/symptoms	Diagnosis or symptoms

DMH consult notes	11 (44%)	13 (52%)	13 (52%)

Physician notes	1 (.06%)	8 (32%)	8 (32%)

Discharge summary	4 (16%)	11 (44%)	11 (44%)

Nursing Notes	-	14 (56%)	14 (56%)

ICD-9 diagnosis code	7 (28%)	-	7 (28%)

Unique veterans including DMHC notes	14 (56%)	16 (64%)	16 (64%)

Unique veterans excluding DMHC notes	9 (36%)	16 (64%)	16 (64%)


	Number	Average bleeding volume (ml)	Average exposure time (min)

Group A	34	8.2 ± 2.3	3.2 ± 2.1

Group B	32	6.8 ± 1.2	2.8 ± 1.7

Group C	36	15.4 ± 1.3	3.6 ± 2.5


	Odds ratio	P

Oxygen treatment	4,27	<0,01

Systolic BP < 100	3,28	<0,01

Heart rate > 110	2,14	<0,01

Respiratory rate > 22	2,71	<0,01

SpO2 < 94 %	1,67	<0,01


Predictor variables	Regression Type	R2[1]	SSE [2]	Significance F (p<0.05) p value [3]	Model Validation [criterion]	ΔAIC [4]	Preferred model of regression [criterion]

FT4	Linear	0.004	2728.62	0.6533	Reject model [3]	-2.61	Polynomial [1,2,4]

Polynomial	0.09	2501.08	0.1026	Reject model [3]

Pretreatment period	Linear	0.07	2539.30	0.0502	Reject model [3]	-23.88	Polynomial [1,2,4]

Polynomial	0.43	1558.26	<0.0001	Accept model [3]

CO	Linear	0.35	1763.9	<0.0001	Accept model [3]	-9.54	Polynomial [1,2,4]

Polynomial	0.48	1418.57	<0.0001	Accept model [3]

Age	Linear	0.48	1411.17	<0.0001	Accept model [3]	-9.08	Polynomial [1,2,4]

Polynomial	0.58	1144.82	<0.0001	Accept model [3]

Systolic BP/24h	Linear	0.81	497.04	<0.0001	Accept model [3]	-0.09	Polynomial [1,2,4]

Polynomial	0.83	477.79	<0.0001	Accept model [3]

PVR	Linear	0.84	427.39	<0.0001	Accept model [3]	-5.39	Polynomial [1,2,4]

Polynomial	0.86	371.74	<0.0001	Accept model [3]


Protein name	Corresponding gene name	Primers: Forward (F) & Reverse (R)

Caspase 3	CASP3	F: 5’-CGGAAGCAGTGCAGACGCGG-3’

R: 5’-GCTGCGAGCACTCACGAAACTCTTC-3’

Bcl-2	BCL2	F: 5’-TCAACCGGGAGATGTCGCCCC-3’

R: 5’-ACAAAGGCATCCCAGCCTCCGTT-3’

Bax	BAX	F: 5’-AAACTGGTGCTCAAGGCCC-3’

R: 5’-TGAGGAGTCTCACCCAACCA-3’

Cytochrome c	CYCS	F: 5’-ATGGTCTCTTTGGGCGGAAG-3’

R: 5’-CTCCCCAGATGATGCCTTTGT-3’

Collagen I	COL1A1	F: 5’-ACGAAGACATCCCACCAATC-3’

R: 5’-AGATCACGTCATCGCACAAC-3’

Collagen III	COL3A1	F: 5’-GCCTCCCGGAAGTCAAGGAGAAAG-3’

R: 5’-CTTTAGGACCGGGGAAGCCCATG-3’

αSMA	αSMA	F: 5’-CTGCTGAGCGTGAGATTGTC-3’

R: 5’-CTCAAGGGAGGATGAGGATG-3’

GAPDH	GAPDH	F:5’-TCTTTTGCGTCGCCAGCCGAG-3’

R:5’-TGACCAGGCGCCCAATACGAC-3’


	Side of Surgery

Baseline INVOS	Left surgery	Right surgery S	P

Left baseline INVOS	67.96 ± 7.30	65.91 ± 8.80	NS

Right baseline INVO	66.24 ± 6.85	65.66 ± 8.99	NS


Ingredients	Content (%)	Nutrients (3)

Corn	64.5	Digestible Energy, MJ/kg	13.81

Whey powder	5.0	Crude Protein (%)	19.82

Soybean meal	23.0	Calcium (%)	0.70

Fish meal	5.0	Total Phosphorus (%)	0.64

L-Lysine HCl	0.2	Lysine (%)	1.22

CaHPO4	0.7	Sulfur Amino Acid (%)	0.65

Pulverized Limestone	0.3	Threonine (%)	0.75

NaCl	0.3	Trptophan (%)	0.22

Premix (2)	1.0

Total	100.0


Atypical antipsychotics	Typical antipsychotics	Alternatives

Clozapine	Haloperidol	Individual therapy

Risperidone	Loxapine	Family therapy

Olanzapine	Molindone	Skill building and psychoeducation


	Clinical presentation and Symptoms

GIST localization	GI bleeding	Abdominal pain	Acute abdomen	Palpable mass	Asymptomatic

Gastric	8	11	-	2	6

Duodenal	2	1	-	-	-

Jejunal	1	1	2	1	2

Small bowel	2	1	3	1	1

Rectal	1	2	-	-	-

Esophageal	-	1	-	-	-

EGIST	-	1	-	1	-


Code	Value	% age	Description

J	190	9.3	Translation, ribosomal structure and biogenesis

A	0	0.0	RNA processing and modification

K	144	7.1	Transcription

L	102	5.0	Replication, recombination and repair

B	0	0.0	Chromatin structure and dynamics

D	31	1.5	Cell cycle control, cell division, chromosome partitioning

V	52	2.6	Defense mechanisms

T	56	2.8	Signal transduction mechanisms

M	105	5.2	Cell wall/membrane biogenesis

N	14	0.7	Cell motility

U	21	1.0	Intracellular trafficking and secretion

O	57	2.8	Posttranslational modification, protein turnover, chaperones

C	60	2.9	Energy production and conversion

G	177	8.7	Carbohydrate transport and metabolism

E	132	6.5	Amino acid transport and metabolism

F	90	4.4	Nucleotide transport and metabolism

H	79	3.9	Coenzyme transport and metabolism

I	66	3.2	Lipid transport and metabolism

P	79	3.9	Inorganic ion transport and metabolism

Q	25	1.2	Secondary metabolites biosynthesis, transport and catabolism

R	133	6.5	General function prediction only

S	108	5.3	Function unknown

-	434	21.3	Not in COGs


Parameters	At start of CRRT	During dialysis period

Creatinine, mg/dl	2.7 ± 1.3

eGFR, CKD-EPI	24.7 ml/minute

Cystatin C, mg/dl	3.2 ± 1.1

GFR, cystatin C	17.7 ml/minute

Bilirubin, mg/dl	9.5 ± 10.6	7.9 ± 6.8

Albumin, g/L	24.7 ± 7.0	25.0 ± 4.1

Cholinesterase, ×1000 IE/L	2.8 ± 1.7	2.6 ± 1.2

ICG-PDR	7.6 ± 5.8	9.9 ± 6.3

MELD score	29.8 ± 5.1


Questions about physical activity counseling	Possible answers

Relevance

It is important that physical activity programs for the community are offered by the health system.	(a) Strongly disagree (b) Disagree (c) Agree (d) Strongly agree

Viability of offering physical activity programs at primary health care units.	(a) Yes (b) No

Priority in offering physical activity programs in health units.	(a) Yes (b) No

Who is the main health professional responsible for promoting physical activity in the unit?	(a) Physician (b) Nurse (c) Physical education professional (d) Nutritionist (e) Physiotherapist (f) Others

What difficulties do you face with regard to physical activity counseling?	(a) Lack of knowledge (b) Lack of time (c) Lack of places for physical activity practice nearby the unit (d) Others

Physical activity assessment

Do you usually ask about the physical activity level of your patients?	(a) Yes (b) No

If so, what method do you employ?	(a) General questions about engagement in physical activity (b) Specific questions about sedentary time (c) Questions about duration, type and intensity of activities (d) Standardized questionnaires (e) Other method

Knowledge about physical activity guidelines

How do you rate your knowledge about the current recommendations on physical activity for health?	(a) Know enough (b) Would like to learn more (c) Have insufficient knowledge

What is the minimum number of days per week that individuals should perform of physical activity of moderate intensity in order to achieve health benefits?	__ days per week

On these days, what is the minimum time recommended to obtain health benefits?	__ __ __ minutes

How should moderate-intensity physical activity be performed to have a positive impact on health?	(a) One bout per day (b) Can be done in 2–3 bouts per day

What is the minimum number of days per week that individuals should perform of physical activity of vigorous intensity in order to achieve health benefits?	__ days per week

On these days, what is the minimum time recommended to achieve health benefits?	__ __ __ minutes

How should vigorous-intensity physical activity be performed to have a positive impact on health?	(a) One bout per day (b) Can be done in 2–3 bouts per day

People can combine moderate-intensity activities (e.g. walking) with vigorous-intensity activities (e.g. running) for meeting physical activity guidelines?	(a) Strongly disagree (b) Disagree (c) Agree (d) Strongly agree


Enzyme	Extension rate (nt/s)	Processivity (nt)	Kd [DNA] (nM)

Taq (wt)	50	20	102

Taq 42	85	20	2.75

Taq 1C2	ND	ND	1.9

E507K	85	20	1.1

G59W	ND	ND	91.6


Symbol	Entrez Gene ID	Description

AHRR	57491	Aryl-hydrocarbon receptor repressor

AKR1C3	8644	Aldo-keto reductase family 1, member C3

AXIN2	8313	Axin2

BCL6	604	B-cell CLL/lymphoma 6

BIRC3	330	Baculoviral IAP repeat containing 3

CARD15	64127	Nucleotide-binding oligomerization domain containing 2

CAT	847	Catalase

CCL5	6352	Chemokine (C-C motif) ligand 5

CCNH	902	Cyclin H

FTHFD	10840	Aldehyde dehydrogenase 1 family, member L1

GATA3	2625	GATA binding protein 3

GSTM3	2947	Glutathione S-transferase mu 3 (brain)

HSD17B4	3295	Hydroxysteroid (17-beta) dehydrogenase 4

IGF1R	3480	Insulin-like growth factor 1 receptor

IL1A	3552	Interleukin 1, alpha

INSR	3643	Insulin receptor

MASP1	5648	Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor)

MBD2	8932	Methyl-CpG binding domain protein 2

MMP1	4312	Matrix metallopeptidase 1 (interstitial collagenase)

MYBL2	4605	V-myb myeloblastosis viral oncogene homolog (avian)-like 2

NEDD5	4735	Septin 2

OPRM1	4988	Opioid receptor, mu 1

PARP4	143	Poly (ADP-ribose) polymerase family, member 4

PGR	5241	Progesterone receptor

PIM1	5292	Pim-1 oncogene

RERG	85004	RAS-like, estrogen-regulated, growth inhibitor

TNKS	8658	Tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase

TP53I3	9540	Tumor protein p53 inducible protein 3

XPC	7508	Xeroderma pigmentosum, complementation group C


Variable	SCI dogs (n = 44)	Healthy control dogs (n = 21)

Dogs

Median age	5.75 years	3 years

MFS at admission	2.5	N/A

TSCIS at admission	6	N/A

Injury to anesthesia time	36.5 h	N/A

Sex characteristics

Female intact	4 (9 %)	0 (0 %)

Female spayed	18 (41 %)	3 (14 %)

Male intact	8 (18 %)	5 (24 %)

Male neutered	14 (32 %)	13 (62 %)

Breeds

Dachshund	34 (76 %)	0 (0 %)

Labrador retriever	0 (0 %)	7 (33 %)

Mixed breed	4 (9 %)	5 (24 %)

Injuries

T12–13	6 (14 %)	N/A

T13–L1	13 (30 %)	N/A

L1–L2	5 (11 %)	N/A

L2–L3	8 (18 %)	N/A

Other thoracic	8 (18 %)	N/A

Other lumbar	4 (9 %)	N/A

Treatments

Non-steroidal anti-inflammatory drugs	17 (39 %)	0 (0 %)

Glucocorticoids	14 (32 %)	0 (0 %)

Both	3 (<1 %)	0 (0 %)


Variable	Value

Body length (from snout to vent) (cm)	45.07 ± 2.83

Length of tail (cm)	6.07 ± 0.85

Length of left vas deferens from testis to vent (cm)	15.30 ± 1.21

Length of right vas deferens from testis to vent (cm)	11.74 ± 1.003

Weight of right testis (mg)	123.07 ± 16.01

Weight of left testis (mg)	93.07 ± 17.02

Volume of right testis (mL)	0.12 ± 0.03

Volume of left testis (mL)	0.06 ± 0.01

Length of right testis (mm)	21.77 ± 3.70

Length of left testis (mm)	16.69 ± 3.95


Extract	Total saponina	Rg1 	Re 	Rd

Content (%)	Content (%)	Content (%)	Content (%)

GTS	66.9 ± 1.5	4.9 ± 0.2	3.4 ± 0.1	1.6 ± 0.1


Variable	Carotid Score	m-IMT	Left Ventricular Mass

Age	r = 0.53p < 0.01	r = 0.46p < 0.01	-

Weight	-	-	r = 0.53p < 0.01

Height	-	-	r = 0.38p < 0.05

Body Mass Index	-	-	-

Waist Circumference	-	-	r = 0.57p < 0.001

Systolic BP	-	-	-

Diastolic BP	-	-	-

Pulse Pressure	-	-	-

Heart Rate	-	-	-

Total Cholesterol	-	-	-

HDL Cholesterol	-	-	-

Total/HDL Ratio	-	-	-

Triglycerides	-	-	-

Glucose	-	-	-

Insulin	-	-	-

Creatinine	-	-	-

Uric acid	-	-	-

Progetto CuoreScore	r = 0.55p < 0.001	r = 0.36p < 0.05	-

Progetto CuoreScore – Logarithm	r = 0.54p < 0.01	r = 0.43p < 0.05	-


Characteristic	Coefficient (95% CI)	p-value

Treatment regimen		0.04

 Prophylaxis	10.0 (0.7, 19.3)

 On-demand	reference

Chronic painb		0.03

 Moderate to severe	−10.0 (−19.2, −0.8)

 None to mild	reference


Subgroups	HR	95% CI	P Value

Patients with diabetes mellitus	0.36	0.14 to 0.90	0.03

Patients without diabetes mellitus	0.74	0.41 to 1.33	0.32

Patients with hypertension	0.57	0.36 to 0.92	0.02

Patients with hyperlipidemia	0.93	0.38 to 2.27	0.89

Patients with normal lipids	0.47	0.26 to 0.83	0.009

Patients with prior myocardial infarction	1.36	0.30 to 6.1	0.70

Patients with no prior myocardial infarction	0.57	0.35 to 0.94	0.02

Patients with major cardiac adverse events	0.30	0.08 to 1.13	0.07

Patients with no major cardiac adverse events	0.59	0.36 to 0.97	0.04


•	‘I would prefer to see the same consultant in hospital, as I trust her already and would find it hard to build the same level of trust with someone else’

•	‘Continuity of care- New consultant may not read all information or interpret it differently’

•	‘A relationship of trust with your own consultant takes time to build and could never be done with a stranger that you meet now and again’

•	‘I’d prefer the above mainly for comfort and familiarity. I’ve shared my condition and stories enough times; having to repeat everything is pointless and counterproductive. It feels like an exercise in futility’

•	‘Continuity of care. I feel it would be best for me to have my care managed by someone who is familiar with me and can compare my symptoms with when I am well’

•	‘Over the past 5 years, I have had annual review as an outpatient and have seen a few different psychiatrists each time. I would prefer to be seen by one psychiatrist and also if admitted to hospital to see the same one’

•	‘Seeing the same doctor means you do not have to repeat your illness every time as this can be upsetting’

•	‘On one hand having the same consultant might give a sense of security. On the other hand, a different consultant having slightly different experiences, may also be a good thing-My personal view is that I would rather choose to have the same consultant’


Medium		Score

Ham's F-12	+10% FCS	180

DMEM/Ham's F-12 (1:1)	+10% FCS	170

Medium199	+10% FCS	165

DMEM	+10% FCS	165

McCoy's 5A	+10% FCS	140


Author, Year, Citation	Sample size*	Respondents who reported the PtDA was balanced.n (%)	Did the PtDA include side-by-side display of evidence?	Did the PtDA include any side-by-side display?

Mathieu, Barratt et al., 2010 [14]	117	66 (57%)	no	no

Smith, Trevena et al., 2010 [15]	334	160 (48%)	no	no

Griffith, Fichter et al., 2008 [6]	106	17 (16%)	unclear	unclear

Spunt, Deyo et al., 1996 [16]	239	133 (56%)	unclear	unclear

Anderson, Carter et al., 2011 [17]	19	17 (89%)	no	yes

Watson, Hewitson et al., 2006 [18]	468	439 (94%)	no	yes

Drake, Engler-Todd et al., 1999 [19]	38	27 (71%)	yes	yes

Lalonde, O’Connor et al., 2004 [20]	16	13 (80%)	yes	yes

van Tol-Geerdink, Stalmeier et al., 2006 [21]	150	142 (95%)	yes	yes

van Tol-Geerdink, Leer et al., submitted [22]	153	147 (96%)	yes	yes


Position of the tapes	at 3 months after surgery	at 6 months after surgery	at one year after surgery

Proximal third of the urethra	3,92 %	9,81 %	9,81 %

The middle third of the urethra	88,23 %	82,35 %	82,35 %

Distal third	7,84 %	7,84 %	7,84 %


Semester	Nominees	Non-nominees

Weekday	Weekend	Weekday	Weekend

Semester 1	97	63	28	8

Semester 2	303	144	42	13


Test	Strain H-6	Alteromonas macleodii

Starch hydrolysis	+	+

Catalase	+	+

H2S production	+	+

Gelatin hydrolysis	+	+

Indole test	–	0

Methyl-red test	–	+

Voges-Proskauer test	–	–

Citrate utilization	–	0

Arginine utilization	+	0

Phenylalanine utilization	–	0

Glucose utilization	+	+

Lactose utilization	+	+

Sucrose utilization	+	+

Gram reaction	G−	G−


		2004	2005

		dry season	rainy season	global	dry season	rainy season	global

Data	Mean	0.390	0.311	0.351	0.166	0.212	0.190

	SD&	0.385	0.260	0.330	0.241	0.257	0.250

Kriging model		Ordinary	Ordinary	Ordinary	Ordinary	Universal	Ordinary

Transform data		No	No	No	No	No	No

Trend Removal		No	No	No	No	Yes	No

Searching Neighborhood	Radius (m)	9924.7	9509.9	9509.9	9924.7	9509.9	9924.7

	Angle	0	0	0	0	0	0

Prediction error measurements	Mean	0.021	0.005	0.012	0.005	0	-0.0004

	MSE#	0.435	0.302	0.338	0.157	0.113	0.102

	Average Stand. Error	0.4	0.282	0.308	0.144	0.11	0.102

	SMSE$	1.09	1.074	1.098	1.088	1.015	1.006


	Medical Costs	Costs per Hypoglycemia Event	Costs per Cardiovascular Events	Weight Gain Costs (transition costsa)	Total Costs (without transition costsa)

Metformin monotherapy	$24	$0	$141	$0	$165

Metformin+DPP-4i	$3524	$0	$330	$0	$3854

Metformin+DPP-4i + Basal insulin	$7170	$1	$366	$0	$7537

Metformin+SU	$40	$4	$441	$148	$486

Metformin+SU + Basal insulin	$3686	$1	$366	$0	$4054


Agricultural sector	Specific application areas	References

Agronomy/Horticulture	Crop protection	[2,33]

Cultivar selection & discrimination	[34,35,44]

Pesticide detection	[33,45–48]

Plant cell culture	[36]

Biotechnology processes	Monitoring	[49,50]

Botany	Floral odors	[37]

Plant identification	[30]

Plant volatiles detection	[30,38,39]

Taxonomic determinations	[30]

Cell culture	Plant growth	[36]

Chemistry	Chemical detection & identification	[51]

Classification	[52,53]

Ecology	Niche roles in ecosystem	[30]

Plant and animal species identification	[30]

Entomology	Detect insects or induced plant volatiles	[54–56]

Insect identification and plant damage	[57–61]

Environmental hazards	Ecosystem management	[30]

Explosive vapors	[62–64]

Health hazards monitoring	[5,65–70]

Toxic gas detection	[71–77]

Water contamination detection	[78–81]

Food production	Chemical contaminants	[82]

Microbial pathogens or toxins	[83,84]

Forestry/Silviculture	Classify/identify wood types	[30,85]

Forest health protection	[2,86]

Forest management	[30]

Industrial Processes	Process monitoring control	[87,88]

Formulation development	[89]

Quality control	[90]

Microbiology	Discrimination of strains	[91–95]

Identification of microbes	[96]

Microbial growth phases	[97]

Pathogen detection	[98]

Toxin production	[99]

Monitoring	Enzyme and protein activity	[100]

Humidity	[101,102]

Immunoglobulin levels	[103]

Oxygen levels	[104]

Plant volatiles	[39]

Physiological conditions	Disease effects on plant physiology	[31,32]

Fruits	[105]

Plant Pathology	Crop protection against bioterrorism	[2]

Disease detection and monitoring	[2,106–112]

Host identification	[30,85]

Host physiology (pathogenesis effects)	[31,32,105]

Host resistance	[113]

Pathogen identification	[2,106]

Post-harvest decay or rot detection	[114–118]

Wood decay fungi	[2,86,96,119,120]

Wood decay types	[2,86]

Waste management	Monitoring malodorous emissions	[23,121–125]

Wood science	Wood identifications	[30,85,126]


Pathways	Map B	No. of genes	No. of TFs

00010: Glycolysis/gluconeogenesis	Carbohydrate metabolism	57	14

00500: Starch and sucrose metabolism	Carbohydrate metabolism	32	12

00520: Amino sugar and nucleotide sugar metabolism	Carbohydrate metabolism	48	20

00620: Pyruvate metabolism	Carbohydrate metabolism	39	22

00030: Pentose phosphate pathway	Carbohydrate metabolism	25	14

00630: Glyoxylate and dicarboxylate metabolism	Carbohydrate metabolism	18	30

00250: Alanine, aspartate and glutamate metabolism	Amino acid metabolism	32	22

00290: Valine, leucine and isoleucine biosynthesis	Amino acid metabolism	11	30

00310: Lysine degradation	Amino acid metabolism	43	26

00230: Purine metabolism	Nucleotide metabolism	152	24

00590: Arachidonic acid metabolism	Lipid metabolism	77	21

00591: Linoleic acid metabolism	Lipid metabolism	40	13

00100: Steroid biosynthesisa	Lipid metabolism	18	17

00670: One carbon pool by folate	Metabolism of cofactors and vitamins	17	26

00790: Folate biosynthesisa	Metabolism of cofactors and vitamins	11	28

00900: Terpenoid backbone biosynthesisa	Metabolism of terpenoids and polyketides	13	22

00604: Glycosphingolipid biosynthesis-ganglio seriesa	Glycan biosynthesis and metabolism	15	19

00534: Glycosaminoglycan biosynthesis-heparan sulfate	Glycan biosynthesis and metabolism	24	25


Contig_ID	Log2_Fold_change	AdjP_value	2C FPKM	2 T FPKM	E-value	Protein families

c32642_g1_i1	-3.614	0.0009	3.1	0.3	0	Glycosyltransferase 8 family, Glycogenin subfamily

c38916_g2_i3	-3.232	0.0097	2.9	0.3	1.00E-83	Cyclin family, Cyclin AB subfamily

c44152_g1_i2	-2.667	0.0177	3.8	0.6	0	Cyclic nucleotide-gated cation channel family

c37946_g1_i2	-2.916	0.0244	4.1	0.6	1.00E-132	MAD2 family

c43673_g1_i5	-2.574	0.0313	4.8	0.8	0	Cytochrome P450 family

c44152_g1_i1	-2.545	0.0818	3.1	0.6	0	Cyclic nucleotide-gated cation channel family

c24995_g1_i1	-2.173	0.1794	2.8	0.7	0	WD repeat CDC20/Fizzy family

c25920_g1_i1	-2.094	0.2470	3.7	0.9	6.00E-162	NA

c33730_g1_i3	-1.879	0.3855	2.3	0.7	6.00E-96	HSF family, Class A subfamily


	WC	BMI	PBF	HDL	Triglyceride	LDL	SBP	DBP

Females

 8 year old cohort	<.05	<.05	<.05	<.05	<.05

 11 year old cohort	<.05	<.05	<.05	<.05	<.05

 14 year old cohort		<.05	<.05

Males

 8 year old cohort	<.05	<.05	<.05

 11 year old cohort	<.05	<.05	<.05		<.05	<.05	<.05

 14 year old cohort	<.05	<.05	<.05	<.05	<.05	<.05


Causes of death	Number of deathsn (%)	Cause-Specific Mortality Rate (per 1000 people)

Ch. X – Diseases of the respiratory system, J00-J99	282 (37.1)	3187

Ch. IX – Diseases of the circulatory system, I00-I99	197 (25.9)	2227

Ch. V – Mental and behavioural disorders, F00-F99	81 (10.7)	916

Ch. VI – Diseases of the nervous system, G00-G99	59 (7.8)	669

Ch. I – Certain infectious and parasitic diseases, A00-B99	33 (4.3)	373

Ch. XVIII – Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified, R00-R99	28 (3.7)	317

Ch. XI – Diseases of the digestive system, K00-K93	16 (2.1)	181

Ch. II – Neoplasms, C00-D48	15 (2)	170

Ch. IV – Endocrine, nutritional and metabolic diseases, E00-E90	14 (1.8)	158

Ch. XIV – Diseases of the genitourinary system, N00-N99	10 (1.3)	113

Ch. XVII – Congenital malformations, deformations and chromosomal abnormalities, Q00-Q99	9 (1.2)	102

Ch. XX – External causes of morbidity and mortality, V01-Y98	8 (1.1)	90

Ch. III – Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, D50-D89	3 (0.4)	34

Ch. XIX – Injury, poisoning and certain other consequences of external causes, S00-T98	3 (0.4)	34

Ch. XIII – Diseases of the musculoskeletal system and connective tissue, M00-M99	2 (0.3)	23

Ch. XII – Diseases of the skin and subcutaneous tissue, L00-L99	0 (0)	NA

Ch. XVI - Certain conditions originating in the perinatal period, P00-P96	0 (0)	NA


Sample ID	ARW742C (TGg>TGt/c)ddPCRNEB Phusion® Preamplification	ARW742C (TGg>TGt/c)ddPCRInvitrogenTM PlatinumTM SuperFiTM Preamplification

Mutant Droplet Count	Wild-type Droplet Count	Percent Mutant	Mutant Droplet Count	Wild-type Droplet Count	Percent Mutant

JHU Pt 3	4	25067	0.016	38	33611	0.113

JHU Pt 7	0	19753	0.000	0	15958	0.000

PreamplifiedWild-type Genomic DNA	0	17573	0.000	0	37069	0.000

PreamplifiedNo Template Control	0	0	0.000	0	0	0.000

Non-AmplifiedWild-type Genomic DNA	0	31225	0.000	0	31225	0.000

Non-AmplifiedAR W742C Mutant Control DNA	10602	0	100	10602	0	100

Non-AmplifiedNo Template Control	0	0	0.000	0	0	0.000


Domain	Principal cause	Number of patients

Neuromuscular	Parkinsonism syndrome	3

	Unexplained Ataxia	2

	Lower extremity weakness	7

Sensory	Dizziness or vertigo	2

	Visual impairment	4

	Peripheral neuropathy	3

Orthopedics	Osteoarthritis (including foot problems)	8

	Hip problems or deformity	6

CV causes*	Orthostatic hypotension	2

	Postprandial hypotension	1

	Vasovagal syndrome	2

	Carotid sinus hypersensitivity	1


	RECIST	CHOI	mCHOI	MASS

Progressive disease (MASS unfavourable response)	Increase in sum of longest target lesion diameters >20%.orDevelopment of new lesions.orUnequivocal non-target lesion progression.	Increase in lesion sizea > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule.	Increase in lesion sizea > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule.	Increase in lesion sizea > 20% without central necrosis.orDevelopment of new lesions.orNew intratumoral enhancing components.

Partial response (MASS favourable response)	>30% decrease in sum of longest target lesion diameters.	Decrease in target lesion CT enhancement (Hounsfield units) >15% or size >10%	Decrease in target lesion CT enhancement (Hounsfield units) >15% and size >10%	Decrease in lesion size >20%, central necrosis or reduction in attenuation >40 Hounsfield units

Complete response	Disappearance of all target lesions and resolution of lymphadenopathy (<10 mm).	Disappearance of all target lesions	Disappearance of all target lesions	Disappearance of all target lesions

Stable disease (MASS indeterminate response)	None of the above	None of the above	None of the above	None of the above


				k-spaced AA pairs

Feature representation	Composition Vector	PSI-BLAST profile	Binary Encoding	adjacent pairs (dipeptides)	1-spaced pairs	......	p-spaced pairs	Total

Number of features	20	315	380	400	400	......	400	400(p+1)


Ingredient	Herb medicine	Object	Stimulus	Role	related pathway

1, 6-di-O-caffeoyl-β-D-glucopyranoside	Callicarpa nudiflora Hook	Platelet	ADP, AA	αIIbβ3, 5-HT, TXA2, platelet aggregation↓	PI3K/Akt/GSK3β, RhoA

Atractylenolide	Atractylodes macrocephala	Platelet	ADP, collagen, thrombin	platelet aggregation and secretion↓	p38, PI3K/Akt

Andrographolide	Andrographis paniculata	Platelet	Collagen	platelet aggregation, Ca2+, TxB2↓	eNOS/NO/sGC/cGMP, PI3K/Akt/p38/cPLA2, PLCγ2/DAG/PKC

platelet aggregation, Ca2+↓	eNOS/NO/sGC/cGMP, p38/ROS/IKKβ/NF-κB/ERK2

Gomisin J	Schisandra chinensis	EC	None	eNOS, NO↑	Ca2+/CaMI, PI3K/Akt

β-Elemene	Curcuma Wenyujin	EC	None	eNOS, NO↑	PI3K/Akt

Puerarin	Pueraria lobata	EC	TNF-α	eNOS, NO↑	ER/PI3K/Akt, CaMKII/AMPK

Tanshinone IIA	Salvia miltiorrhiza Bunge	Macrophage	Ox-LDL	TF↓	ROS/NF-κB

Platelet	None	Platelet activation↓	ERα/PI3K/Akt

Platelet	ADP	Platelet activation↓	ERK-2

Xuezhikang	Red yeast rice	Macrophage	Ox-LDL	TF↓, SOD↑	NOX/ROS/ERK1/2/NF-κB

Gypenoside XLIX	Gynostemma pentaphyllum	Macrophage	LPS	TF↓	PPAR-α

Salvianolic acid B	Salvia miltiorrhiza Bunge	EC	TNF-α	PAI-1↓	ERK1/2/AP-1 (NF-κB)


Flavonoid	NGF	GDNF	BDNF

Flavanones

 Alpinetin	+++	++	+

 Hesperidin	—	+	—

 Naringenin	—	—	—

 Naringin	—	+++	—

 Neohesperidin	—	++	—

Flavones

 Apigenin	—	++	—

 Baicalein	—	—	—

 Luteolin	++++	++++	++

 Tangeretin	++	—	—

 Wogonin	—	—	—

Aurones

 Sulfuretin	—	++	—

Dihydrochalcones

 Phloretin	—	—	—

Flavonols

 Silybin	++++	—	+

Chalcones

 Cardamonin	+	++	—

Isoflavones

 Calycosin	+++	++++	+++

 Calycosin-7-O-glc	+++	++	—

 Daidzein	—	—	—

 Formononetin	—	—	—

 Genistein	++++	++++	++

 Genistin	—	—	—

 Puerarin	+	+++	—

Flavones

 (−)-Catechin	—	—	+

 (−)-Epicatechin	—	—	—

Flavonols

 Fisetin	+++	—	+

 Galangin	—	++	—

 Hyperin	—	—	—

 Icariin	—	—	+

 Isorhamnetin	++++	++++	+++

 Kaempferol	+	+	+

 Quercetin	—	+	—

 RNFG	—	++	—

 173-estradiol	++++	++++	+++


Gene ID	ENSEMBL Gene ID	Gene name	Base Mean	Fold Change (log2)	p-adj

VIM	ENSECAG00000004216	vimentin	101,873.95	0.49	0.0846

LUM	ENSECAG00000018248	lumican	93,834.08	1.21	0.0000

EEF1A1	ENSECAG00000020363	eukaryotic translation elongation factor 1 alpha 1	80,865.77	0.35	0.4978

FN1	ENSECAG00000000701	fibronectin 1	76,204.43	− 0.03	0.9131

COL3A1	ENSECAG00000024769	collagen type III alpha 1	71,782.03	−0.28	0.3120

COL1A2	ENSECAG00000024740	collagen type I alpha 2	68,527.63	0.03	0.9444

ACTG1	ENSECAG00000018600	actin gamma 1	67,827.73	0.59	0.1648

DCN	ENSECAG00000020413	decorin	66,957.05	0.72	0.0000

CLU	ENSECAG00000007010	clusterin	60,592.80	0.54	0.3689

CTSK	ENSECAG00000019087	cathepsin K	50,743.84	−0.01	0.9822

PSAP	ENSECAG00000021672	prosaposin	42,671.36	−0.71	0.0123

COL6A3	ENSECAG00000020887	collagen type VI alpha 3 chain	39,357.71	−0.81	0.0000

AHNAK	ENSECAG00000014229	AHNAK nucleoprotein	32,777.16	−1.03	0.0004

TPT1	ENSECAG00000018348	tumor protein, translationally-controlled 1	32,069.02	0.86	0.0000

RPL4	ENSECAG00000023179	ribosomal protein L4	28,412.14	0.55	0.0555

ANXA1	ENSECAG00000015794	annexin A1	28,358.48	1.22	0.0000

HSP90AA1	ENSECAG00000018948	heat shock protein 90 alpha family class A member 1	27,249.39	0.36	0.5410

ASPN	ENSECAG00000007047	asporin	27,102.67	1.44	0.0000

EIF4G2	ENSECAG00000014700	eukaryotic translation initiation factor 4 gamma 2	25,563.63	1.26	0.0000

HSPA8	ENSECAG00000013510	heat shock protein family A (Hsp70) member 8	23,372.98	−0.02	0.9496

HTRA1	ENSECAG00000009990	HtrA serine peptidase 1	23,322.81	−0.18	0.7559

APP	ENSECAG00000021011	amyloid beta precursor protein	21,959.94	−0.08	0.7687

CLTC	ENSECAG00000019077	clathrin heavy chain	21,758.80	0.44	0.1597

CTNNB1	ENSECAG00000006949	catenin beta 1	21,082.51	0.57	0.0512

FAP	ENSECAG00000011790	fibroblast activation protein alpha	20,454.17	1.72	0.0000


Treatment category

Cat I	Treatment for new patients with first-line anti-TB drugs (2 months of INH, RIF, EMB, PZA/4 months of INH, RIF)

Cat II	Re-treatment regimen with first-line anti-TB drugs (2 months of STR, INH, RIF, EMB, PZA/1 month of INH, RIF, EMB, PZA/3 months of INH, RIF, EMB)

New	A patient who has never had treatment for TB or who has taken anti-TB drugs for <1 month

Close contact	Close contacts of MDR-TB patients who develop active TB

Failure	A patient previously treated for TB who is started on a re-treatment regimen after previous treatment has failed

Relapse	A patient who was previously declared cured or treatment completed and is diagnosed with bacteriologically-positive (sputum smear or culture) TB

Standard MDR-TB regimen	6 months of AMK, PZA, LFX, ETH, DCS/18 months of PZA, LFX, ETH, DCS a


Contact Stress, GPa	Rolling Time, h	Rolling Speed, rpm	Condition

2.5	12, 24	1000	dry

3.0


	Screening	Randomization	3 monthlyFU	6 monthlyFU	End of study

25(OH)D3 serum levels		X	X(when 25(OH)D3 levels >80 ng/ml and study drug temporarily interrupted)	X

Blood sample for DNA analysis		X

Hemoglobin, Hematocrit	X				X

WBC count and differentiation	X			X	X

RBC count	X				X

Platelet count	X				X

Renal function (creatinine)	X				X

Liver function (AF, ALT, gamma-GT, LDH)	X				X

Serum calcium	X		X		X

Serum phosphate	X		X		X

Albumin	X				X

24 h urine calcium					X


Author, date	No. Participants = n	Avg age at start	Cast changed	Avg days in casts - ‘fast’ group	Tenotomy rate	Follow up	Comment

Morecuende, 2005	230(non-random)	Not stated	5 days	30	85%	Study ran over 11 years	Older study, NR sample

Harnett, 2011	40(RCT)	21 days	3 / week	16	79%	Min 6 mthsAve 8 mths	Youngest children

Xu, 2011	26(RCT)	92 days	2 / week	20.6	87%	2–6 years	Manipulation time of 2 min

Ullah, 2014	28(RCT)	18 weeks	2 / week	23.3	80%	Not reported

Elgohary, 2015	41(RCT)	11 weeks (SD 7)	2 / week	18.1 (SD 3)	91%	12–48 mths	Relapse rate 15% both groups

RCT data summary	RCTsn = 135	11 weeks	2/week	19.5 days	84% average	1 year(3 RCTs)	Young infants, 2 min. Stretch


	Bacteria	Methanogens

Community	Similarity	Pseudo- F	P-value	Similarity	Pseudo- F	P-value

Treatment effect		4.54	0.007		9.06	0.003

Pairwise comparisons

 CON versus CHI	59.5	2.33	0.046	76.0	1.09	0.360

 CON versus IVY	73.9	1.62	0.118	62.4	3.10	0.024

 CHI versus IVY	60.1	2.17	0.048	60.7	7.00	0.003


Code Level 3	Label level 3	Assigned land use type

111	Continuous urban fabric	Urban

112	Discontinuous urban fabric	Urban

121	Industrial or commercial units	Urban

122	Road and rail networks and associated land	Urban

123	Port areas	Urban

124	Airports	Urban

131	Mineral extraction sites	Urban

132	Dump sites	Urban

133	Construction sites	Urban

141	Green urban areas	Urban

142	Sport and leisure facilities	Urban

211	Non-irrigated arable land	Arable

212	Permanently irrigated land	Arable

213	Rice fields	Arable

221	Vineyards	Arable

222	Fruit trees and berry plantations	Arable

223	Olive groves	Arable

231	Pastures	Grassland

241	Annual crops associated with permanent crops	Arable

242	Complex cultivation patterns	Arable

243	Land principally occupied by agriculture, with significant areas of natural vegetation	Grassland

244	Agro-forestry areas	Forest

311	Broad-leaved forest	Forest

312	Coniferous forest	Forest

313	Mixed forest	Forest

321	Natural grasslands	Grassland

322	Moors and heathland	Grassland

323	Sclerophyllous vegetation	Grassland

324	Transitional woodland-shrub	Forest

333	Sparsely vegetated areas	Grassland


Function	P-value	No. of Genes

Cellular movement	2.10E-35 to 3.60E-05	584

Cell death	1.99E-30 to 3.56E-05	853

Cellular development	2.08E-29 to 3.43E-05	730

Cellular growth and proliferation	3.01E-28 to 2.40E-05	912

Cellular assembly and organization	1.24E-15 to 3.32E-05	460


Food Groups	Factor I Meat–Instant Food Dietary Pattern	Factor II Vege–Seafood Dietary Pattern	Factor III Cereal–Dairy Dietary Pattern

Milk	−0.174	0.047	0.597

Dairy products	0.038	0.058	0.634

Eggs	0.471	0.131	0.154

Meat	0.552	0.265	−0.037

Organ meats	0.313	0.127	0.036

Legumes/soy products	0.331	0.354	0.146

Seafood	0.312	0.400	0.070

Light-colored vegetables	−0.055	0.815	0.078

Dark-colored vegetables	−0.084	0.841	0.080

Fruit	−0.063	0.440	0.355

Vegetables with oil/dressing	0.278	0.569	−0.053

Rice/flour products	0.295	−0.011	0.521

Whole grains	−0.039	0.089	0.441

Root crops	0.126	0.241	0.397

Refined dessert	0.327	0.226	−0.079

Jam/honey	0.317	−0.066	0.453

Sugary drinks	0.524	−0.173	0.154

Rice/flour cooked in oil	0.405	0.011	0.238

Deep-fried food	0.674	0.111	−0.030

Instant noodle	0.397	−0.115	−0.009

Processed food	0.611	0.051	0.053

Sauce	0.549	0.076	−0.035


	Cases	sCD157 <31.02 ng/ml	sCD157 ≥31.02 ng/ml	P value*

MPM, n	61	30	31

Age at diagnosis, y				0.062

 mean ± SD		73.07 ± 10,46	77.39 ± 6.76

 median (range)		73.50 (52–94)	79.00 (61–89)

Sex				0.106

 Male	40	23	17

 Female	21	7	14

Histologic subtype				0.951

 Epithelioid	47	23	24

 Sarcomatoid	5	3	2

 Biphasic	2	1	1

 NOSa	7	3	4

Cytology				0.359

 negative	21	13	8

 positive	21	9	12

 suspicious	19	8	11

PMNb (n = 54)				0.516

 <10 cells × 10 (HPF, 200×)c	36	17	19

 10–50 cells × 1 (HPF, 200×)	14	8	6

 >50 cells × 10 (HPF, 200×)	4	1	3

CD157 expression in biopsy tissues (n = 29)				0.06

 H-score <110	11	8	3

 H-score ≥110	18	6	12

Follow-up (n = 54)				0.005

 DODd	43	17	26

 AWDe	11	10	1


Partition number	Cluster number	BRCA1	BRCA2	Number of genes selected

1	1	0	4	80

	2	7	4

2	1	7	4	110

	2	0	4

3	1	5	3	73

	2	2	5

4	1	6	0	61

	2	1	8


	pN0 and pN1	pN2 and pN3	p-value

Percentage of positive tumors cells	47.12 +/- 29,.3	55.62 +/- 26.33	0.068

Staining intensity	1.22 +/- 0.82	1.43 +/- 0.75	0.036*


Variables	Name and source of the original scales and items	α	Items (n)

Socio-demographic factorsa		18

Health behaviour

 Physical activity	Health Questionnaire age 18–64 years [29]	–	1

 Dietary habits	Food Frequency Questionnaire [30]	–	15

 Smoking	Health Questionnaire age 18–64 years [7]	–	2

 Alcohol consumption	AUDIT-C [31, 32]	–	3

Health status

 General health status	Survey in vocational schools in Bielefeld [36]	–	1

 Diseases and complaints	Work Ability Index – Questionnaire [33]	–	6

 Self-efficacy	Self-efficacy scale [24]	0.85	10

 Irritation	Irritation scale [22]	0.88	8

Occupational situation and prospects

 Job satisfaction	COPSOQ: German standard version [23, 34]	0.81	7

 Job strain and prospects	Additional questions (e.g., taking into account the current work situation, do you want to stay in this profession for the next five years?)	–	3


PROCEDURE	ONCOLOGIC RESULTS

RARC*	equivalent lymph node yields	comparable overall and recurrence-free survival	similar positive surgical margins in ≤ T2 disease

RAPN§	comparable margin status	equivalent local recurrence rates

RALNU#	studies with long-term follow-up are needed


Comorbidity	ICD codes

Heart failure	ICD-8:	427, 428

ICD-10:	I42, I50, I110, J819

Ischaemic heart disease	ICD-8:	411, 412, 413, 414

ICD-10:	I20, I23, I24, I25,

Anemia	ICD-8:	280-285

ICD-10:	D60-D69

Cancer	ICD-8:	140-209

ICD-10:	C00-C97

Chronic obstructive pulmonary disease	ICD-8:	490, 491, 492

ICD-10:	J42, J44

Atrial fibrillation	ICD-8:	427.4

ICD-10:	I48

Acute myocardial infarction	ICD-8:	410

ICD-10:	I21, I22

Peripheral arterial disease	ICD-8:	443

ICD-10:	I70, I74

Diabetes	ICD-8:	250

ICD-10:	E10-E14

Hypertension	ICD-8:	400, 401

ICD-10:	I109, I119, !959, I270, I951


Advantages	Shortcomings

Available anywhere on the earth in any weather conditions for outdoor measurements at no cost	High cost of professional equipment

Tri-dimensional positioning with centimeter accuracy (Real Time Kinematics, RTK mode)	Not fully validated for gait analysis yet

No space restriction: freedom in the path selection, including uphill/downhill locomotion.	Limited time windows (2–4 h per day)

Free living conditions, i.e close to real life	One body segment measured only (head): Because of mandatory constant satellite access, the antenna must not be obstructed by body parts.

Unlimited number of consecutive strides: limited only by the memory capacity of the receiver and the duration of the batteries.	Outdoor analysis: difficult to standardize environmental conditions (weather, terrain).

	Not fully miniaturized (cumbersome antenna).


Operation (Pipette-dependence modea)	Purpose	Details

PF	1	Input (I-mode)	Liquid charging into MMV wells	Figure 1c

2	Output (O-mode)	a. Transfer	Complete ejection of liquid in wells	Figure 1b and Additional file 6: Figure S5

b. Washing

3	Square transfer (S-mode)	Fractional volume transfer	Additional file 2: Figure S1

4	Z-direction transfer (Z-mode)	Normal transfer of liquid into wells	Figure 1b and Additional file 5: Figure S4

5	X-direction transfer (X-mode)	Division of liquid in all wells	Additional file 7: Figure S6

6	Magnetic beads transfer (M-mode)	a. Beads recovery	Beads recovery	Additional file 8: Figure S7

b. Division of liquid	Division of liquid in all wells	Additional file 9: Figure S8

7	Filtering (F-mode)	Filter-selective transfer	Figure 2a

PD	8	Pipette-dependent transfer (P-mode)	a. Manual	Manual transfer of liquid or beads	Additional file 10: Figure S9

b. Robotic	Robotic transfer of liquid or beads	Additional file 3: Figure S2


Gene	Sequence (5′-3′)	Product size (bp)

IL-6	For: CCTGACCCAACCACAAATGC	646

Rev: CCTTAAAGCTGCGCAGAATGA

IL-8	For: CTTTCCACCCCAAATTTATCAAAG	264

Rev: AGAGCTCTCTTCCATCAGAAAGCT

GAPDH	For: ACACCCACTCCTCCACCTTT	199

Rev: TAGCCAAATTCGTTGTCATACC


	EAPs for sensing

	pros	cons

ionic EAPs

 conducting polymers	chemical stability, miniaturization, facile fabrication process, low-cost, low-weight, biocompatibility, soft, multiformable (sheet, film, tubular, trilayer), response to mechanical, electrical, chemical and thermal stimulation	insufficient adhesion onto substrate, fragile upon mechanical and thermal loading

 ionic polymer–metal composites	low-weight, biocompatibility, miniaturization, soft, large produced voltage signal, sensitive to large bending deformation, ability to work in wet environments	hysteresis, sensitive to moisture and temperature during operation, operation limited to low temperature due to liquid electrolyte, slow response

 carbon nanotubes	high surface area to volume, high sensitivity, miniaturization, directional mechanical and electrical properties	expensive, slow response, difficult to control intrinsic properties during fabrication

electronic EAPs

 dielectric elastomers	large sensing range, low-cost, light-weight, stability in many working cycles, and capability as self-sensing actuators	defect-sensitive, rare for stress measurement, not sensitive to compression in normal direction, may be affected by temperature

 liquid-crystal elastomers	potential for high strain changes, potential high sensitivity to strain	complex and expensive synthesis and processing of the materials

 piezoelectric polymers	wide bandwidth, fast electromechanical response, relatively low-power requirements, high generative forces	relatively low output performance originating from charge dissipation. Some materials need to be stretched and poled to gain higher output


Drug resistant plasmid Name	Antimicrobial drug	Drug resistance plasmid MIC (ug/ml)	Empty vector MIC (ug/ml)	Fold increase

pAMP	ampicillin	16	4	4

pAMP	piperacillin	3	2	1.5

pAMP	cefotaxime	<.25	<.25	0

pAMP	ceftazidime	<.5	<.5	0

pAMP	cefepime	0.064	0.094	0.68

pAMP	Aztreonam	0.19	0.125	1.5

pAMP	Imipenem	0.25	0.25	0

pCIP	ciprofloxacin	0.125	<0.002	>62.5

pCIP	levofloxacin	0.38	0.012	31.7

pCIP	Ampicillin	6	4	1.5

pCIP	piperacillin	3	2	1.5

pCIP	ceftazidime	<.5	<.5	0

pCIP	cefotaxime	<.25	<.25	0

pCIP	cefepime	0.125	0.094	1.3

pCIP	Imipenem	0.25	0.25	0

pTMP	trimethoprim	>32	0.124	>258

pTMP	trimethoprim- sulfamethoxazole	0.5	0.064	7.8

pAZT	Aztreonam	12	0.125	96

pAZT	cefepime	1	0.094	10.6

pAZT	ceftazidime	16	0.5	32

pAZT	piperacillin	12	2	6

pSXT	trimethoprim-sulfamethoxazole	1	0.064	15.6

pSXT	trimethoprim	>32	0.125	>256

pPRP:1B	ciprofloxacin	0.125	0.016	7.8

pPRP:1B	levofloxacin	0.25	0.047	5.3


Primers	Sequences	Denaturation	annealing	Cycles	PCR products

HGF: ForwardReverse	5'-CAGAGGGACAAAGGAAAAGAA-3'5'-GCAAGTGAATGGAAGTCCTTTA-3'	94°C, 15s	58°C, 60s	40	167 bp

KGF: ForwardReverse	5'-GAACAAGGAAGGAAAACTCTATGCAA-3'5'-AAGTGGGCTGTTTTTTGTTCTTTCT-3'	94°C, 15s	60°C, 60s	40	201 bp

HGF-R: ForwardReverse	5'-GTTTACTTGTTGCAAGGGAGAAGACT-3'5'-TAGGGTGCCAGCATTTTAGCA-3'	94°C, 15s	58°C, 60s	40	88 bp

KGF-R: ForwardReverse	5'-TTAAGCAGGAGCATCGCATTG-3'5'-AACATCCAGGTGGTACGTGTGAT-3'	94°C, 15s	60°C, 60s	40	151 bp

Ubiquitin-c: ForwardReverse	5'-CACTTGGTCCTGCGCTTGA-3'5'-TTTTTTGGGAATGCAACAACTTT-3'	94°C, 15s	60°C, 60s	40	105 bp


True/False item	Correct answer	% correct*	True/False item	Correct answer	% correct*

HIV/AIDS KNOWLEDGE	 	 	OVERDOSE KNOWLEDGE

When a couple decides that they are ONLY going to have sex with each other, they no longer need to use condoms to prevent HIV.	F	66.9 (62.1, 71.8)	Causing physical pain will help keep someone who is overdosing conscious or alive.	F	36.9 (31.9, 41.9)

The fewer sex partners you have in your life, the less likely you are to get HIV.	T	66.0 (61.2, 70.9)	Fatal ODs are more likely to happen when people use alone.	T	89.5 (86.4, 92.6)

People can still transmit the HIV/AIDS virus even if they test negative for the virus.	T	45.2 (40.1, 50.3)	People are more likely to have an OD if they use soon after getting out of a government center, prison, or detoxification program.	T	84.8 (81.1, 88.5)

Most people who have HIV know they have it.	F	52.1 (46.9, 57.2)	Most heroin OD deaths happen very quickly, in less than 15 minutes after taking the drugs.	F	9.8 (6.7, 12.8)

HEPATITIS KNOWLEDGE	 	 	It is easy to tell the difference between a “heavy nod” and a heroin overdose.	F	10.1 (7.0, 13.2)

Hepatitis can cause liver cancer.	T	72.1 (67.5, 76.7)	Sweating and anxiety are signs of a heroin OD.	F	58.0 (52.9, 63.1)

HIV is easier to transmit than hepatitis.	F	46.4 (41.3,51.6)	Injecting water can slow or reverse the effects of an opioid overdose	F	30.5 (25.7, 35.2)

You will be able to recognize if any individual is infected with hepatitis.	F	40.9 (35.8, 46.0)	Someone who is overdosing should be immediately placed on their back.	F	18.3 (14.3, 22.3)

Most people infected with hepatitis know that they have the disease.	F	46.4 (41.2, 51.6)	Naloxone is a medication for reversing the effects of a heroin OD.	T	47.7 (42.4, 53.0)

Drinking alcohol worsens the course of hepatitis C.	T	84.2 (80.4, 87.9)	Naloxone must be injected into a vein.	F	26.9 (22.2, 31.7)

You are more likely to get hepatitis B than hepatitis C by having unprotected sex.	T	54.3 (49.1, 49.4)	Naloxone will reverse a stimulant overdose.	F	24.8 (20.3, 29.4)


Productivity software	Microsoft Office

	Endnote

	Toolbook Runtime (with modules)

Medical Software (Anatomy)	A.D.A.M

	Anatomy TV

	Grant's Atlas of Dynamic Human Anatomy

	Netter

	Imaging Modalities

	D.A.R.T.O.S.

Medical Software (Biochemistry)	Buffers

	Clustal X

	Cn3D

	Genedoc

	Graphpad Prism

	Growcyt

	Hypercell 98

	Image J

	Interactive biochemistry

	NjPlot

	Protein explorer

	Protein purification lab

	RasMol 2.6

	Spectrophotmetry

	Swiss PDB Viewer

	Trace

Medical Software (Nutrition and Dietetics)	FoodWorks

	SERV v5.5e

Medical Software (Pharmacology)	Pharma-Cal-Ogy

Medical Software (Physiology)	Acid Base

	Exercise Physiology


Number	Scenario

1	Human papilloma virus positive state

2	Cervical intraepithelial neoplasia grade I

3	Cervical intraepithelial neoplasia grade II/III

4	Cervical cancer requiring simple or radical hysterectomy

5	Cervical cancer requiring radical hysterectomy and subsequent radiotherapy (and chemotherapy)

6	Cervical cancer requiring chemoradiation therapy

7	Cervical cancer requiring chemotherapy without surgery

8	Condyloma (genital warts [condyloma acuminatum])


Parameter	HMA All Lines (n = 88)	First-Line HMA (n = 41)	First-Line ICT (n = 122)	p-Value First-Line HMA vs. ICT

Median age at diagnosis, years	69	73	60	0.1698

 (min–max)	(28–88)	(44–88)	(20–86)

Male gender, n (%)	54 (61)	26 (63)	88 (72)	0.3919

BM blasts at start of treatment

 Median	22	22	24	0.8576

 Mean (Standard Deviation)	25.8 (17.2)	25.8 (15.9)	27.1 (15.8)

 Unknown, n (%)	12 (14)	2 (5)	6 (5)

Hemoglobin at start of treatment, n (%)

 ≤10 g/dL	55 (63)	32 (78)	32/64 (50)	1.00

 Pts. with unknown hemoglobin	3 (3)	0 (0)	71 (58)

Median WBC count at start of treatment, ×109/L (min–max)	2.35	2.42	1.81	0.7294

(0.1–32.3)	(0.6–24.0)	(0.2–23.9)

Neutrophil count at start of treatment, n (%)

 ≤ 0.5 × 109/L	34 (39)	18 (44)	18/57 (31)	0.7326

 Pts. with unknown neutrophil count	5 (6)	1 (2)	79 (65)

Platelet count at start of treatment, n (%)

 ≤50 × 109/L	54 (61)	24 (69)	62 (51)	0.8673

 Unknown	3 (3)	0 (0)	10 (8)

AML subtype, n (%)

 Primary	66 (75)	35 (85)	81 (66)	0.4373

 Secondary	11 (13)	4 (10)	17 (14)

 Unknown	11 (13)	2 (5)	24 (20)

MRC cytogenetic risk group, n (%)

 Good risk	1 (1)	0 (0)	0 (0)	0.6943

 Intermediate risk	39 (44)	17 (42)	51 (42)

 Poor risk	45 (51)	22 (54)	53 (43)

 Unknown	3 (3)	2 (5)	18 (15)


Molecular Category	TGFβ Sub-Family Pathway 1	BMP Sub-Family Pathway

Ligands	TGFβs, ActivinsGDF8/9/10/11, BMP3, Nodal	BMP2/4/5/6/7/8/9/10, GDF1/3/5/6/7, MIS

Type II receptors	TβRII, ActRIIA, ActRIIB	BMPRII, ActRIIA, ActRIIB

Type I receptors	ALK4, TβRI (ALK5), ALK7	ALK1/2, BMPR1A (ALK3), BMPR1B (ALK6)

R-Smad	Smad2/3	Smad1/5/8

Co-Smad	Smad4	Smad4

I-Smad	Smad7	Smad6/7


Comparison	p value	r value

Quads Strength and TWT

Baseline	0.003	-0.688

Week 6	0.003	-0.697

Week 12	0.005	-0.662

Quads Strength and TST

Baseline	0.008	-0.626

Preoperative	0.020	-0.552

Week 6	0.009	-0.618

Week 12	0.001	-0.776

Quads Strength and TCT

Preoperative	0.032	-0.508

WOMAC-Pain and TCT

Baseline	0.047	0.464

WOMAC-Function and TWT

Baseline	0.034	0.252

SF36-Physical Health and TWT

Baseline	0.009	-0.623

Week 12	0.041	-0.481

SF36-Physical Health and TST

Preoperative	0.039	-0.487

SF36-Mental Health and TCT

Week 12	0.026	-0.528


	FMF

	Rheumatic diseases (+)	Rheumatic diseases (–)

	n = 26	n = 166	p

Male/female	4/22	79/87	0.002

Age at onset (years), mean ± SD	39.3 ± 15.8	29.0 ± 16.8	0.006

Fever	24 (92.3 %)	160 (96.4 %)	0.296

Frequencies of febrile attack (per month), mean ± SD	1.01 ± 0.59	1.06 ± 0.96	0.523

Duration of fever attack (days), mean ± SD	3.0 ± 2.2	3.8 ± 4.1	0.359

Abdominal pain	3 (11.5 %)	74 (44.6 %)	0.001

Thoracic pain	4 (15.4 %)	47 (28.3 %)	0.165

Arthritis	21 (80.8 %)	87 (52.4 %)	0.007

Erysipelas-like erythema	3 (11.5 %)	31 (18.7 %)	0.281

AA amyloidosis	0	7 (4.2 %)	0.355

Family history of periodic fever	1 (3.8 %)	38 (22.9 %)	0.025


MicroRNA	Location	Model	Response	References

miR-200c	Upstream	db/db T2DM	Increase aorta endothelial dysfunction	[101]

miR-320	Upstream	High glucose treated HUVECs	Reduced expression of ET-1, VEGF, and FN	[102]

miR-133a	Upstream	STZ-induced diabetes	Prevent cardiac fibrosis	[103]

miR-1 and 6	Up stream	STZ-induced diabetes and high glucose treated NRVCs	Increase cardiomyocyte apoptosis	[104]


Cheese sample	Area assessed	a value at 144 days

Control	Top	−2.22

Side	−2.17

Base	−2.32

Center	−2.38

Exp1	Top	−2.21

Side	−2.28

Base	−2.21

Center	−1.95

Exp2	Top	−2.18

Side	−2.16

Base	−2.10

Center	−1.34b

Exp3	Top	−2.14

Side	−2.35

Base	−2.13

Center	−1.82


	Low Rate 	Medium Rate 	High Rate 	p-value

Countries with implemented screening programmes	22% (2/9)	67% (6/9)	89% (8/9)	0.014

Countries with guidelines for screening	11% (1/9)	78% (7/9)	78% (7/9)	0.005


	Reported obstetric complications or near misses

Independent variables	Eclampsia	Hemorrhage	Sepsis	Obstructed labor

	(n = 324)	(n = 4,945)	(n = 3,120)	(n = 2,847)

	Odds ratio	Odds ratio	Odds ratio	Odds ratio

Biological factors

Age 18–35 years (ref)

Age <18 years	1.35***	1.20***	1.18***	1.27***

Age >35 years	1.34***	1.27***	1.19*	1.21***

Parity 1–2 (ref)

Nulliparity	1.13**	1.10**	1.14**	1.30***

Parity >2	1.12	1.09	1.05	1.10

No previous stillbirth or miscarriage (ref)

Adverse obstetric history	1.18***	1.06**	1.12**	1.14***

MUAC ≥ 21.5 cm (ref)

MUAC < 21.5 cm	1.04	1.12*	1.16*	1.05

Socioeconomic factors

Wealth index – Lowest quartile (ref)

Wealth index - 2nd quartile	1.00	1.01	1.02	1.00

Wealth index - 3rd quartile	1.01	1.02	1.00	1.00

Wealth index - Highest quartile	1.00	1.03	1.05	1.02

Maternal illiteracy (ref)

Maternal literacy	1.01	1.01	1.04	1.03

Psychosocial factors

Both partners wanted pregnancy (ref)

Only one partner wanted pregnancy	1.02	1.06	1.08	1.07

Neither partner wanted pregnancy	1.02	1.40***	1.37***	1.28***


Supernatant conditions	Protein concentration (mg/mL)	Degradation (%)

Culture supernatant	0.24 ± 0.03	50.48 ± 2.40

Super filtered culture supernatant a	1.22 ± 0.04	73.84 ± 1.65

Boiled culture supernatant	0.12 ± 0.02	52.24 ± 1.74


	Full follow-up scenario	Early mortality scenario

....Hazard ratio (95 % CI)...

cART	Yes	0 · 41 (0 · 18, 0 · 92)	0 · 28 (0 · 16, 0 · 49)

No	1 · 0	1 · 0

Cotrimoxazole	Yes	0 · 06 (0 · 01, 0 · 26)	0 · 02 (0 · 01, 0 · 07)

No	1 · 0	1 · 0

TB cure	Yes	0 · 38 (0 · 18, 0 · 84)	0 · 66 (0 · 38, 01 · 13)

No	1 · 0	1 · 0


Variables	AEP monitor group (n= 19)	RSS monitor group (n= 18)	P

Median number of propofol dosage adjustment	6 [5-7]	3 [2-3.8]	<0.001

Time to the first adjustment of the propofol dosage (second)	137 [117.5-200.5]	466 [376.5-553.5]	<0.001

Propofol dosage during examination (μg⋅kg-1⋅min-1)	43.5 [28.5-49.3]	24.2 [15.5-32.4]	0.025

Fentanyl dosage during examination (μg⋅kg-1⋅hr-1)	2.5 [1.8-3.1]	2.7 [1.9-3.4]	0.679

Percentage of propofol dosage change compared with the baseline dose (%)	93.5 [48.4-172.3]	39.5 [30.4-53.9]	0.011

Percentage of time at sedation target (%)	51.3 [47.0-63.5]	15.4 [9.5-23.5]	<0.001

Percentage of AAI levels greater than 40 during examination (%)	35.3 [27.1-51.5]	84.5 [76.5-90.4]	0.033

Patients with significant hypotension (MAP less than 60 mmHg) (%)	2 (10.5)	0 (0)	0.154

Duration of FB examination (min)	29 [27-32]	30 [28-32]	0.860

EMG (dB)	18 [16-23.5]	20 [17-25]	0.751


Background characteristics	Total %

Total 85 participants

Age in years

≥20	7.7

21-30 yrs	37.2

31-40 yrs	14.1

41-50 yrs	9

≤ 50	3.8

Missing data	28

Education

Illiterate	26.9

1 to 5 yrs	6.4

6 to 10 yrs	35.9

≤ 12 yrs	11.6

Missing data	19.2

Place of last birth

No child	1.3

Pregnant	3.8

Home	30.8

Govt	15.4

Private	26.9

Missing data	21.8

Number of children

No child	7.1

Pregnant	9.0

1 child	14.1

2 children	24.7

3 to 4 children	38.5

more than 4 children	4.7

missing data	1.3


CNVs	Copy numbers	Related genes	Related pathways

rs2002594; rs1986617	1	FAM162A	Mitochondrial apoptotic cascades

rs10517547; rs10517548; rs2122642; rs2345041; rs1823535; rs1823536; rs1470724	1	LPHN3	G-protein-coupled-receptor proteolysis

rs764223	1	PGAM1	Glycolysis/gluconeogenesis; metabolism of carbohydrates

rs137964; rs10483201	1	GRAP2	T cell receptor signaling pathway

rs10491333	4	HLA-DQB1	Antigen processing and presentation

rs2895201	4	SPTLC1	Sphingolipid metabolism

rs1988981; rs1321555; rs1358815; rs1964875;	4	PRIM2	Purine and pyrimidine metabolism; telomere maintenance

rs3797819; rs10515399; rs1896582; rs1366081; rs9326759	4	FER	Adherens junction

rs342597; rs10507638; rs10507639	3	DIAPH3	Regulation of actin cytoskeleton

rs10520675; rs10520671; rs7167737; rs1948066; rs10520673; rs965313	3	NTRK3	MAPK pathway

rs6816712; rs2911940; rs10517654; rs10517655; rs7662187; rs10517658	3	PDGFC	Cytokine-cytokine receptor interaction; Focal adhesion; Gap junction

rs855858; rs855860; rs10489736	3	ROR1	transmembrane receptor protein tyrosine kinase signaling pathway

rs2912	3	GAB2	Fc epsilon RI signaling pathway

rs10491050; rs7092874; rs7904118	3	SORCS1	neuropeptide signaling pathway

rs10485060; rs9322451; rs1852629	3	OPRM1	Neuroactive ligand-receptor interaction

rs1060447; rs4919231; rs1932796; rs716838; rs2169462; rs10509722	3	HPSE2	Glycosaminoglycan degradation


Gene symbol	Description	Position (Mb)	MiRNA	Packages

RNF111	Ring Finger Protein 111	6.32–6.36	miR-142-3p	Targetscan

TCF12	transcription factor 12	6.90–7.00	miR-142-5p	MIRDB, TargetscanPicTar

ARPP19	cAMP–regulated phosphoprotein, 19 kDa	8.23–8.24	miR-142-5p	Targentscan

MYO5A	myosin VA (heavy chain 12, myoxin)	8.24–8.33	miR-142-3p	Targentscan

MAPK6	Mitogen–Activated Protein Kinase 6	8.42– 8.45	miR-142-5p	Targentscan


Variable	Number	Percentage

Intravenous drug users	20	5.8

Surgery	144	41.6

Blood transfusion	40	11.6

Transplantation	1	0.3

History of hepatitis in the family	186	53.8

Uterine curettage	12	11.9a

Dialysis	13	3.8

Dental manipulation	292	84.4

Tattoo	54	15.6

Ear Piercing	91	26.3

Circumcision	243	99.2b

High-risk sex	6	1.7

Phlebotomy	60	17.3


 	Perprotocol	Intention to treat

 	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value

Age

 <60 years old	1.0 (referent)	 	1.0 (referent)

 ≥60 years old	1.33 (0.61–2.92)	0.478	1.16 (0.55–2.47)	0.696

Gender

 Male	1.0 (referent)	 	1.0 (referent)

 Female	1.14 (0.53–2.46)	0.737	1.18 (0.57–2.44)	0.648

Resident area

 Urban	1.0 (referent)	 	1.0 (referent)

 Rural	1.49 (0.65–3.42)	0.342	1.12 (0.53–2.37)	0.775

Endoscopic finding

 With peptic ulcer	1.0 (referent)	 	1.0 (referent)

 Without peptic ulcer	1.05 (0.48–2.26)	0.909	1.05 (0.51–2.16)	0.900

Treatment

 CAR	1.0 (referent)	 	1.0 (referent)

 LAcR	2.67 (1.22–5.84)	0.014*	2.57 (1.24–5.33)	0.011*


 	σ (MPa)	STD	λ	STD

SV- Longitudinal	5.38	0.6	1.32	0.04

SV- Circumferential	2.61	0.67	1.55	0.06

UV- Longitudinal	1.65	0.11	1.33	0.04

UV- Circumferential	0.97	0.19	1.90	0.16


Platform	System	Applications

	IMU	GPS	LIDAR	Camera	DG payload weights	Cost	Large area	Small area	Mobility	Weather limitation	DG accuracy (3DRMS)	Cyber city	Rapid Disaster Relief

Fixed wing aircraft	Tactical grade	Geodetic grade	Yes	Digital/film	> 50 kg	High	Yes	Yes	Low	High	< 20 cm	Yes	Low

Helicopter	Tactical grade	Geodetic grade	Yes	Digital	> 50 kg	High	No	Yes	Low	High	< 20 cm	Yes	Low

UAV	MEMS	L1 phase	Yes	Digital	< 25 kg	Low	No	Yes	High	Low	< 50 cm	Yes	High

UAV Helicopter	MEMS	L1 phase	Yes	Digital	< 10 kg	Low	No	Yes	High	Low	< 50 cm	Yes	High


 	No. of points

Risk factor	SITS SICH risk score	Extended risk score

Aspirin + clopidogrel	3	3

Aspirin monotherapy	2	2

NIHSS ≥13	2	2

NIHSS 7-12	1	1

Blood glucose ≥180 mg/dL	2	2

Age ≥72 y	1	1

Systolic blood pressure ≥146 mm Hg	1	1

Weight ≥95 kg	1	1

Onset-to-treatment time ≥180 min	1	1

History of hypertension	1	1

Total anterior circulation infarct	N/A	3

Maximal total points	12	15*


Treatment	Flume number	Field name

Sustainable intensification	6	Golden Rove

Increased use of legumes	8	Higher Wyke Moor and Middle Wyke Moor (reseeding in 2013)

11	Dairy East

Planned reseeding	10	Lower Wheaty

15	Longlands East (reseeding in 2013)


Characteristics	Count (%)

Sociodemographic

 Gender

Male	98 (65.3)

Female	52 (34.7)

 Age (years)

20–30	80 (53.3)

31–40	48 (32.0)

41–50	22 (14.7)

 Education level

Vocational school	58 (38.7)

Diploma or equivalent	62 (41.3)

Bachelor degree or higher	30 (20.0)

 Monthly income (Baht)

<9000	96 (64.0)

≥9000	54 (36.0)

Behavioral

 Smoke cigarettes

No	70 (46.7)

Yes	80 (53.3)

 Drink alcohol

No	86 (57.3)

Yes	64 (42.7)


		Parametric	Nonparametric

Misacylation

	COVE	68*	55

	resCOVE	64	64

	Spacer	55	64

	Usage	38	48

COVERes COVE

	Spacer	46	46

		64	73*

	Usage	67	62

		57	52

Spacer	Usage	55	55

Processing	Misacylation		82*/46

	COVE		82*/82*

	res COVE		55/55

	Mis-COVE	82*/46	64/55

	Mis-res COVE	73*/55	64/55

	Mis-Usage	55/20	64/30

	COVE-Usage	55/90*	55/80*

	Res COVE-Usage	46/80*	46/70


 Age/sex	Comorbidity	Site	Culture source	Therapy	Outcome

75/F	Syringomyelia	L leg	Tissue	Antibiotics, debridement	Survived

80/F	None	R leg	Tissue	Antibiotics, debridement	Survived (skin graft)

49/F	None	L ankle	Tissue	Antibiotics, debridement	Survived

75/M	None	R leg	Tissue	Antibiotics, debridement	Survived

71/M	None	L foot	Skin/bulla	Antibiotics, debridement	Survived (skin graft)

59/M	Not stated	R leg	Skin/blister	Antibiotics, debridement	Died

64/F	Diabetes mellitus	Both legs	Tissue	Antibiotics	Died

65/F	Rheumatoid arthritis	R arm	Blood/tissue	Antibiotics, amputation	Died

52/M	Diabetes mellitus	R leg	Tissue	Antibiotics, debridement	Survived

52/M	Diabetes mellitus	R leg	Tissue	Antibiotics, debridement	Survived

59/M	Hairy-cell leukemia	L leg	Blood/tissue	Antibiotics, debridement	Survived

58/M	Cirrhosis	L leg	Tissue	Antibiotics, debridement	Died

49/F	Rheumatoid arthritis	R leg	Blood/skin	Antibiotics	Died

48/M	None	R leg	Tissue	Antibiotics, debridement	Survived

77/F	Rheumatoid arthritis	R leg	Tissue/blood	Antibiotics	Died

2/M	Vascular/lymphatic malformation	Perineum	Tissue/stool	Antibiotics, debridement	Survived


Outcome	All births

	n	Rate	OR (95% CI)	AORa (95% CI)

Umbilical artery pH < 7.10

 Occiput posterior	56	5.5	1.48 (1.12–1.96)	1.28 (0.93–1.74)

 Occiput anterior	733	3.8	reference	reference

Metabolic acidaemia

 Occiput posterior	2	0.2	1.15 (0.28–4.80)	0.64 (0.08–5.04)

 Occiput anterior	33	0.2	reference	reference

Apgar score < 7 at 5 min

 Occiput posterior	20	1.5	2.18 (1.37–3.47)	1.84 (1.11–3.05)

 Occiput anterior	188	0.7	reference	reference

Neonatal care

 Occiput posterior	38	2.9	1.87 (1.33–2.62)	1.68 (1.17–2.42)

 Occiput anterior	420	1.6	reference	reference

Composite morbidityb

 Occiput posterior	47	3.6	1.87 (1.38–2.54)	1.66 (1.19–2.31)

 Occiput anterior	520	2.0	reference	reference


Material	Scaffold Preparation	Shape and Structure of the Scaffold	Mechanical Properties of the Scaffold	Ref.

Collagen	Freeze drying	Sponges L = 11, 23 or 51 mm94% porosity, pore size = 62 μm	For L = 23 mm spec. EM = 0.02 MPaLinear Stiffness = 0.05 N/mmMaximum Stress = 0.005 MPa	[38,39]

Collagen/Chondroitin Sulfate	Sponge pore size = 53 μm	Linear Stiffness = 0.025 N/mm	[87]

Collagen/Chondroitin Sulfate	Isotropic sponge pore size = 87 μmAnisotropic pore sizes = 55, 152, 243 μm	ND	[51,55]

Collagen	Extrusion	EDC Crosslinked fiber diameter = 215 μmEDC/EDGE Crosslink diameter = 137 μm	Fiber diameter 215 μm → EM = 19.3 MPaFiber diameter 137 μm → EM = 46.2 MPa	[52,53]

Collagen	ELAC	Collagen thread diameter = 50–100 μm	ND	[33]

Collagen	Woven collagen scaffold with 81% of porosity	Stiffness = 23.8 N/mm	[34]

PLGA	Electrospinning	Random nanofibers = 568 nmAligned fibers = 320, 680 and 1800 nm	Random nanofibers → EM = 107 MPaAligned fibers → EM = 341–510 MPa	[105,106]

PLLA	Aligned nanofiber diameter = 430 nmRandom nanofiber diameter = 450 nm	Aligned nanofibers → Stiffness = 3.48 N/mm; EM = 22.76 MPaRandom nanofibers → Stiffness = 0.07 N/mm; EM = 0.63 MPa	[30]

PLDLLA	Crimped fiber diameter = 880 nmAmplitude = 5.2 μmWavelength = 46 μm	Crimped fiber Modulus = 3 MPa	[54]

PEEUR	Aligned or random fiberdiameters <1 μm, 1–2 μm or >2 μm	EM = 4.2–9.2 MPa	[45,46]

PCL	Yarned made of twisted aligned fibers (200 μm diameter)	UTS = 17 MPaEM = 30 MPa	[35]

P(LLA-CL)/Collagen	Fiber diameter = 643 nmFinal yarn thickness = 150 μmPore size = 28.5 μm	Yarns EM = 2 MPaUltimate deformation = 250%	[107]

PLGA	Knitting	Scaffold with 3 yarns. 20 filaments/yarn25 μm diameter of filament + electrospun nanofibers	Initial failure load = 56.3 NInitial Elastic Stiffness = 5.80 N/mmInitial toe region Stiffness = 0.34 N/mm	[36]

Silk	Combined knitted silk fibers and silk sponge pores size from 20 to 100 μm	Maximum Tensile Load = 252 NTensile Stiffness = 40 N/mm	[37]

Silk/Collagen	Combined knitted silk scaffold and freeze dryed collagen sponge	Failure force = 21.65 N	[97]


Demographic characteristics	Sampled frequency, n (%)	Weight misperception frequency, n (%)

Sexa

 Female	2003 (44.5)	426 (21.4)

 Male	2380 (55.5)	900 (39.1)

Race/ethnicityb

 American Indian/Alaskan Native	50 (0.6)	17 (30.7)

 Asian	111 (2.2)	33 (20.8)

 Hispanic/Latino	1672 (25.3)	457 (28.3)

 Multiple Race/Ethnicities Non-Hispanic	223 (5.1)	67 (23.3)

 Native Hawaiian/other Pacific Islander	29 (0.6)	8 (37.2)

 Non-Hispanic black or African American	479 (14.5)	202 (41.0)

 Non-Hispanic white	1819 (51.8)	542 (31.0)

Grade in schoolc

 9th	1120 (26.4)	376 (35.6)

 10th	1129 (26.6)	357 (30.7)

 11th	1152 (24.3)	330 (30.2)

 12th	982 (22.7)	263 (27.7)


Task	Group description	Activity of group 1 higher that group 2	Activity of group 1 low that group 2	Reference

Tactile stimulation	PD patients (1) vs. healthy control volunteers	R. primary sensory, R. motor cortex, R. supplementary motor area, B. caudate, B. precuneus, B. occipital visual cortex, L. and M. temporal gyrus		(23)

Time perception task	PD patients (1) vs. healthy control volunteers and medical patients (2)	Precuneus (after long stimuli)		(26)

Gambling	Non-Pathological gamblers whit PD (1) vs. Pathological gamblers with PD (2)	B. anterior cingulate cortex, M. and S. frontal gyri, precuneus, R. I. parietal lobule, ventral striatum		(24)

Imaginary gait	PD patients experiencing freezing (1) vs. PDs not experiencing freezing (2)	R. globus pallidus, R. supplementary motor area, R. mesencephalic locomotor region, R. cerebellum, B. anterior insula, B. ventral striatum, B. pre-supplementary motor area, L. sub-thalamic nucleaus		(28, 29)

Hand movement	PD patients with (1) and without (2) mirror movements syndrome	R. dorsolateral prefrontal cortex, M. prefrontal cortex, Pre-supplementary motor area, Occipital Cortex	B. insula, B. posterior cingulate cortex, L inferior frontal cortex	(27)

Balloon analog risk task	PD patients with an impulse-control disorder (1) vs. PD patients without and impulse-control disorder (2)	R. ventral striatum		(25)

Speech	PD patients (1) vs. healthy control volunteers	Primary orofacial sensorimotor cortex		(20)

Saccade	PD patients (1) vs. healthy control volunteers	Frontal and supplementary eye fields	L. and R. cerebellum contralateral motor cortex	(22)

Finger tapping	PD patients (1) vs. healthy control volunteers	Putamen, supplementary motor area	R. prefrontal cortex, R. caudate	(21)


Motor nerve conduction

Nerve	Latency	Amplitude	Conduction velocity

Median R (wrist)	8.9 ms	1.3 mV

Median R (elbow)	18.5 ms	0.8 mV	24 m/s

Ulnar R (wrist)	4.4 ms	6.9 mV

Ulnar R (below elbow)	10.4 ms	5.7 mV	38 m/s

Ulnar R (above elbow)	13.4 ms	3.3 mV	33 m/s

Tibial R (ankle)	6.2 ms	3.4 mV

Tibial R (popliteal fossa)	23.1 ms	0.7 mV	24 m/s


	No. of abnormalities

Abnormality	Arctic	Innoko	Kenai	Tetlin	Yukon Delta	Total

Eye abnormality

 Anophthalmia (missing eye)	0	2	12	6	0	20

 Unpigmented iris (black eye)	0	15	118	20	1	154

 Microphthalmia (small eye)	0	0	1	1	0	2

 Othera	0	2	6	2	0	10

Skeletal injuryb

 Brachydactyly (short digits)	2	0	7	0	2	11

 Ectrodactyly (missing digits)	1	1	4	3	0	9

 Ectromelia (partial limb)	0	0	44	6	0	50

 Limb crushed	0	0	14	1	2	17

 Otherc	0	2	2	0	0	4

Skeletal malformation

 Amelia (missing limb)	0	1	31	3	0	35

 Anteversion (twisted long bones)	0	0	9	0	0	9

 Brachygnathia (short jaw)	1	4	6	0	0	11

 Microcephaly (shrunken head or blunt snout)	0	0	4	0	0	4

 Micromelia (shrunken limb or limb element)	5	3	126	17	3	154

 Polymelia (extra limb)	0	0	1	0	0	1

 Polydactyly (extra digits)	2	0	2	0	0	4

 Scoliosis or lordosis (curved spine)	0	0	2	0	0	2

 Cutaneous fusion (skin webbing)	0	0	3	0	0	3

 Syndactyly (digits fused)	0	0	11	2	0	13

 Taumelia (bone bridge or triangle)	0	0	4	0	0	4

Skeletal unknown origin

 Kinked tail	0	0	3	0	0	3

 Brachydactyly (short digits)	0	1	27	1	2	31

 Ectrodactyly (missing digits)	0	0	26	3	0	29

 Ectromelia (partial limb)	7	12	90	14	2	125

 Otherd	0	2	5	0	0	7

Overall

 Eye total	0	19	137	29	1	186

 Injury total	3	3	71	10	4	91

 Malformation total	8	8	199	22	3	240

 Unknown origin total	7	15	151	18	4	195

Total abnormalities	18	45	558	79	12	712

Total abnormal individuals	12	39	450	68	7	576

Total individuals examined	615	1,309	5,716	1,146	482	9,268

Percent individuals abnormal	2.0%	3.0%	7.9%	5.9%	1.5%	6.2%


	pCR prediction(n = 488)

Prediction evaluation*	PPV (SD)	NPV (SD)	Sensitivity (SD)	Specificity (SD)

Unsupervised clustering

BRmet50	93(14)	34(3)	58(3)	83(0.6)

PMID18271932Sig33	92(3)	32(5)	53(6)	83(6)

Anthracycline-taxane Centroid

BRmet50	89(6)	27(0.6)	40(5)	83(6)

PMID18271932Sig33	77(4)	20(3)	29(1)	67(0.5)


Groups	Total cholesterol 	LDL-C	HDL-C	TG	HbA1c	FBG

r Pearson	r Pearson	r Pearson	r Pearson	r Pearson	r Pearson

Ox-LDL of normoalbuminurics	−0.07	−0.085	−0.25	−0.21	−0.024	−0.220

Ox-LDL of microalbuminurics	−0.086	−0.2	−0.28	0.28	−0.379	0.36

Ox-LDL of macroalbuminurics	−0.148	0.066	0.001	−0.139	−0.136	−0.129

Ox-LDL of first degree relatives	 −0.26	0.21	−0.029	0.26	0.03	−0.093

Ox-LDL of control group	0.49	0.33	0.092	0.05	0.057	−0.37


	ABFAB	FBC	FPH	Total

Women who stopped breastfeeding before 6 months	n = 65	n = 7	n = 14	n = 86

Stopped bf before mastitis	5	1	2	8

Stopped within 3 wks	29	2	5	36*

Stopped between 3 and 26 wks	31	4	7	42

Women breastfeeding at 6 months	n = 70	n = 19	n = 31	n = 120

Mastitis in previous 3 wks	2	0	0	2

Mastitis > 3 wks earlier	68	19	31	118

Total women with mastitis				206


Protein ID	Orthologs	Potential functions

Wolco1| 166770	STE20	Growth, virulence, and sclerotial formation

Wolco1| 43954	STE11	Growth, virulence, and sclerotial formation

Wolco1| 150169	STE7	Growth, virulence, and sclerotial formation

Wolco1| 75024	MKK2	Regulate MAPK signaling pathway

Wolco1| 144702	PBS2	Regulate MAPK signaling pathway

Wolco1| 135363	BCK1	Regulate MAPK signaling pathway

Wolco1| 121529	CLA4	Pathogenicity, mycelial growth and conidial morphology


Individual subject characteristics	Prognostic factors

	Age	Confirmatory

	Gender	Exploratory

	Height, weight, body mass index	Exploratory

	Ethnicity/race	Exploratory

Lifestyle factors

	Participation in sports activities or physical fitness level	Exploratory

	Smoking	Exploratory

	Alcohol use	Exploratory

Sociodemographic characteristics

	Marital status	Exploratory

	Level of education	Exploratory

	Income	Exploratory

	Employment status	Exploratory

Nature and severity of the low back pain

	Duration of the low back pain	Confirmatory

	Non-specific	Exploratory

	Radiation	Exploratory

	Previous low back pain treatment received	Exploratory

Comorbidities, e.g., diabetes, heart disease

	Presence of comorbidities	Exploratory

Number of comorbidities	Exploratory

Category of comorbidities	Exploratory

 Type of treatment	Manipulation, mobilization, combination

 Psychosocial factors	e.g., Back Depression Inventory, Fear Avoidance Beliefs Questionnaire	Confirmatory

Treatment preference/ expectation	e.g., preference for treatment, previous experience with treatment, expectation to final improvement, self-efficacy scale/beliefs	Confirmatory


	B	SE	Significance

(Constant)	−0.57	0.05

City of residence	0.25	0.06	0.000*

Smoker(s) present in the home	0.12	0.07	0.073


Tumor Response as per RECIST v1.1	Arm A, N = 3	Arm B, N = 5

Number of patients	Number of patients

CR	0	0

PR	0	0

SD	1	2

PD	2	3


Number of eligible patients	420	Type of procedure

Primary procedures	196	Aesthetic

n = 378	131	Aesthetic and functional

	51	Functional

Revision procedures	31	Aesthetic

n = 42	9	Aesthetic and functional

	2	Functional


	No.	%

Gender

 Male	59	54.13

 Female	50	45.87

Chemotherapy

 Gemcitabine alone	41	37.61

 Gemcitabine combined with other drugs*	68	62.39

Primary pancreas tumor

 Head	50	45.87

 Body or tail	35	32.11

 Unknown	24	22.02

Stage of disease

 Locally advanced	10	9.17

 Metastatic	70	64.22

 Unknown	29	26.61

Distant metastasis

 Liver	50	71.43

 Lung	2	2.86

 bone	4	5.71

 Abdomen	5	7.14


Characteristic		Number (n)	Percentage (%)

Gender	Male	155	55

Female	127	45

Gestational age (weeks)	28–36	115	41

≥37–42	168	59

Postnatal age at measurement	≤24 h	9	3

2 days	54	19

3 days	84	30

4 days	73	25

5–10 days	58	21


Variable	Adjusted odds ratio (95% CI)	SE

CGPA	15.27 [6.28, 27.11]∗∗∗	0.88

Age <30 years	0.31 [0.06, 1.63]	0.85

Male gender	1.13 [0.50, 2.55]	0.42

Home residence (ref = rural)

 Semiurban	1.49 [0.41, 5.37]	0.65

 City/urban	1.44 [0.38, 5.42]	0.68

Father highly educated 	0.56 [0.21, 1.49]	0.49

Mother highly education	1.23 [0.55, 2.76]	0.41

Entered nursing with WASSCE 	0.32 [0.04, 2.63]	1.08

Nursing was a first career of choice	0.50 [0.21, 1.19]	0.45

Read science in formal school	1.2 [0.5, 2.6]	0.40


Gene names	RS	Gene names	RS	Gene names	RS

KRT19	1.6	PTGES2	0.4	BCL7C	0.2

BARD1	1.6	PREX2	0.4	ZNF18	0.2

MST1R	1.5	USP1	0.4	PGLS	0.2

S100A14	1.2	EHF	0.4	CNTN4	0.2

LGALS1	1.2	ADM	0.4	BACH1	0.2

RNF168	1.1	GRM4	0.4	ZFPL1	0.2

TFF1	1	SHFM1	0.4	MAGED2	0.1

SPEN	1	EMP3	0.4	TMEM43	0.1

WDR18	0.9	PTGES	0.3	GALNT5	0.1

RRAS	0.9	TRAF1	0.3	HMX1	0.1

PLEK2	0.8	NAMPT	0.3	RASSF6	0.1

CD248	0.8	BCL2L12	0.3	PFN1	0.1

RHBDL2	0.8	MAML1	0.3	SLC16A7	0.1

CAPN5	0.7	USP24	0.3	ZBTB40	0.1

S100A16	0.7	AMHR2	0.3	MAGED4	0.1

CDC6	0.6	PSMG3	0.3	PIF1	0.1

ENDOG	0.6	NFE2L2	0.3	MBTPS1	0.1

GNG2	0.6	RAPH1	0.3	HDAC4	0.1

CLDN18	0.6	TSHZ2	0.2	VASN	0.1

RNF169	0.5	RNF146	0.2	PSME3	0.1

NR3C1	0.5	NFIL3	0.2	AMN	0.1

TMC8	0.5	SPINK1	0.2	ERCC1	0.1

AKT1S1	0.5	OSTM1	0.2	BRD9	0.1

KLK10	0.5	ESRRG	0.2	B4GALNT1	0.1

SLC2A1	0.5	XRCC3	0.2	PLEKHG5	0.1

ANTXR1	0.4	SLC4A7	0.2	ARHGAP33	0.1

CHSY1	0.4	DPH1	0.2	CYP24A1	0.1

ELAC1	0.4


	SNP-database region

Scan-statistic region	Inter-gene	Within-gene	Regions detected only by scan statistic	Total no. regions

Non-gene scan statistic	33 (8)a	0	72 (12)	105 (20)

Gene scan statistic	10 (7)	38 (17)	87 (20)	135 (44)

Total	43 (15)	38 (17)	159 (32)	240 (64)


Reference	Country	Study design	Sample size	Data source/sample type	Results

[30]	China	The 5th Chinese National Nutrition and Health Survey (2010–2012)	2111	Questionnaire of dietary Mn intake	Men	A decreased risk of MetS with higher Mn intake.

Women	An increased risk of MetS with higher Mn intake.

MetS components	Mn intake was inversely associated with abdominal obesity and hypertriacylglycerolaemia in men, but positively associated with low HDL-cholesterol in both men and women.

[31]	Korea	The Korea National Health and Nutrition Examination Survey (2007–2008)	5136	Questionnaire of dietary Mn intake	Men	No difference

Women/MetS components	The women subjects with high blood pressure showed significantly lower intake of Mn than did control subjects.

[32]	China	Cross-sectional study	Cases: 221 Controls: 329	Questionnaire of dietary Mn intake	Men/women	A lower risk of developing MetS in the second, third, and highest quintiles of Mn intake with respect to the lowest quintile after adjusting age, sex, and energy intake.

MetS components	Daily intake of Mn was decreased with the increasing number of MetS components.

[5]	Poland	Cross-sectional study	313 (men aged 50–75 years)	Serum (Mn level)	Significant positive correlations (Mn–BMI, Mn–abdominal circumference, Mn–waist-to-hip ratio, Mn–insulin, Mn–HOMA-IR), but no correlation with MetS.

[33]	Korea	The Korea National Health and Nutrition Examination Survey (2008)	1405	Whole blood (Mn level)	No difference

Urine (Mn level)	No difference


Theme	Number of mode-sensitive* items of total number of items	Median (and maximum)odds ratio among mode-sensitive items

Health behaviour

Medicine	0/3	-

Smoking habits	0/1	-

Self assessments

Self-esteem	8/9	1.57 (2.57)

Well-being	9/11	1.55 (2.20)

Depression	3/6	2.12 (2.21)

Stress	12/15	1.67 (2.44)


 	Risk of bias	Applicability concerns concerns

First author, year	Patient selection	Index test	Reference standard	Flow and timing	Patient selection	Index test	Reference standard

Beldame, 2011 [23]	?	+	+	-	+	+	+

Boeree, 1991 [24]	-	?	+	+	+	+	+

Decker, 1988 [33]	?	+	?	-	+	+	+

Harilainen, 1987 [25]	+	?	?	-	+	+	+

Katz, 1986 [26]	-	+	?	+	+	+	+

Lee, 1988 [27]	-	+	?	-	+	+	+

Lucie, 1984 [28]	-	+	?	-	+	+	+

Mulligan, 2011 [29]	+	+	?	?	+	+	+

Noyes, 1980 [30]	-	?	+	-	?	+	+

Richter, 1996 [34]	-	+	?	+	+	+	+

Schwartz, 1997 [35]	-	+	+	+	+	+	+

Tonino, 1986 [31]	-	+	?	?	+	+	+

Wagemakers, 2010 [19]	+	+	+	+	+	+	+

Wong, 1999 [32]	+	?	?	+	+	+	+


Tumor stage	N	(%)

Non-invasive carcinoma	24	8.7

Invasive carcinoma

T1	176	61.9

T2	63	22.1

T3	9	3.0

T4	8	3.0

Unknown	4	1.3

Nodal status

N0	187	65.8

≥N1	93	32.7

Unknown	4	1.5

Metastases/recurrence	29	10.4

Treatment

Surgery

BET	224	78.9

Mastectomy	55	19.4

No surgery	5	1.7

SN biopsy	128	45.2

Axillary lymph node dissection	117	41.5

Chemotherapy

Neoadjuvant	24	8.4

Adjuvant	122	42.8

Irradiation	233	81.9

Hormonal therapy	218	76.9

Relationship

Single	16	5.7

Married/living with partner	172	60.5

Divorced/widowed	79	27.8

Unknown	17	6

Education

Compulsory	121	42.2

Post-compulsory	149	52.8

University level	14	5.0

Employment

Employed	77	27.1

Retired	86	30.3

Homemaker/unemployed	88	31.0

Unknown	33	11.6


Primers	5′–3′ sequence (bp)

Primers for 3′-RACE PCR

Kiss1-F	CGCCACAAGCGGCCAAGAAG

Kiss2-F	AGGGCCACATTTCCTGCCGACT

Primers for 5′-RACE PCR

Kiss1-R	CCCGCTTCTTGGCCGCTTGT

Kiss2-R	CCGAACGGATTGCGGTTGAATTTG

Primers for qPCR

Kiss1-F	GGTCTCTTAGGTACACCCCGT	This study

Kiss1-R	ACAGCTCCTCGCTCATTTG

Kiss2-F	ACGGACGACTCAGGTTCTCT	This study

Kiss2-R	GCCCTCGATTTCACTGTCTT

actin-F	AGTATTTGCGCTCGGGTG	Aroua et al. (27)

actin-R	CAGCCTTCCTTCCTGGGT

lhβ-F	TCACCTCCTTGTTTCTGCTG	Aroua et al. (27)

lhβ-R	TAGCTTGGGTCCTTGGTGATG

fshβ-F	TCTCGCCAACATCTCCATC	Aroua et al. (27)

fshβ-R	AGAATCCTGGGTGAAGCACA

gnrh-r1a-F	TGGTCATGAGTTGCTGCTACA	Penaranda et al. (25)

gnrh-r1a-R	AGACACCCCTCTCCGTCTTT

gnrh-r1b-F	TCGTCACGCTCTACGTTGTC	Penaranda et al. (25)

gnrh-r1b-R	AGGCAGGACTCTCCACCTTT

gnrh-r2-F	TCACCTTCTCCTGCCTCTTC	Penaranda et al. (25)

gnrh-r2-R	TTGGAAGATGCCTTCCCTTT


Accession ID	Amplicon Size	Primers used

α ENaC-wt	325 bp	Sense: 5'-TCATGCTGCTACGCCGGTTCC-3'

		Antisense:5'-TCCATCAGTTTACAAGGGAG-3'

α ENaC a	266 bp	Sense: 5'-CAGAGCTCCTGGGGGCGCCTT-3'

		Antisense: 5'-TCCTTCTGTCACGATGGTCA-3'

α ENaC-b	278 bp	Sense: 5'-GGATGATGGTGGCTTCAACT-3'

		Antisense: 5'-ACACCCAGGAGCTCTGCTTT-3'

α ENaC-c	59 bp	Sense: 5'-GCTCCTGGGTGTGATCAACTA-3'

		Antisense: 5'-AAAGAAGGTGGTGGGGATGT-3'

	59 bp	Sense: 5'-GGATGATGGTGGCTTCAACT-3'

		Antisense: 5'-AAAGAAGGTGGTGGGGATGT-3'

α ENaC-d	99 bp	Sense: 5'-CCACGCGTCCGAAGAAAC-3'

		Antisense:5'-AAAGAAGGTGGTGGGGATGT-3'

	99 bp	Sense: 5'-CCACGCGTCCGAAGAAACTG-3'

		Antisense:5'-TAAAGAAGGTGGTGGGGATG-5'

CK479583	767 bp	Sense: 5'-GCCCCAGCAGGGCATGACCC-3'

		Antisense: 5'-CTAGAGTAGCATAGGCAGGT-3'

CK475461	814 bp	Sense: 5'-TCCAAGTATACACAGCAGGT-3'

		Antisense: 5'-TACAGGAGTCAGGCTGTGAG-3'

CK364785	764 bp	Sense: 5'-GGGGCTATTGCTATTATAAA-3'

		Antisense:5'-CCACACAGAGGGCTCGGCGGG-3'

CK475819	748 bp	Sense: 5'-GATTCCCGGGATCTTGGA-3'

		Antisense: 5'-AGGCTGACCATCGTGACAG-3'

CB690980	376 bp	Sense: 5'-CCACGCGTCCGAAGAAAC-3'

		Antisense: 5'-AAAGAAGGTGGTGGGGATGT-3'

Pgk	263 bp	Sense: 5'-GCTGCAGAACTCAAATCTCT-3'

		Antisense:5'-TGTGTGCAGTCCCAAAAGCA-3'


Powders Prepared with Different Process Control Agents	Crystallite Size (nm)	Lattice Constant (Å)	Strain (%)

None	11.8	3.1636	0.688

Ethanol	24.2	3.1549	0.483

Stearic acid	14.7	3.1648	0.590


Region	States	Frequency	IAQ Practice Indexb	Schools with index ≥ 70 (%)

1	Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont	25	71.8	64

2	New Jersey, New York, Puerto Rico,c U.S. Virgin Islandsc	28	71.9	57

3	Delaware, Maryland, Pennsylvania, Virginia, West Virginia, District of Columbia	21	77.0	71

4	Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee	46	64.4	41

5	Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin	87	73.0	60

6	Arkansas, Louisiana, New Mexico, Oklahoma, Texas	40	70.7	60

7	Iowa, Kansas, Missouri, Nebraska	15	66.7	53

8	Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming	13	66.3	54

9	Arizona, California, Hawaii, Nevada, Pacific Islands,c Tribal Nations subject to U.S. law	27	70.1	56

10	Alaska, Idaho, Oregon, Washington	16	77.1	81


County	Pre-treatment	Post-treatment

Number of schools	Number of children	Number of schools	Number of children

Bomet	1	108	1	103

Bungoma	1	108	1	105

Busia	2	214	2	210

Homa Bay	1	108	1	102

Kakamega	2	212	2	213

Kisii	1	105	1	103

Kisumu	3	312	3	313

Kwale	3	317	3	316

Mombasa	1	98	1	108

Narok	2	215	2	214

Taita Taveta	1	102	1	91

Overall	18	1899	18	1878


	Patient 1	Patient 2	Patient 3

Origin	Dominican Republic	Haiti	Haiti

Age (years)	25	52	41

Sex (W/M)	W	W	M

Date of diagnosis (and onset of symptoms)	December 2014	January 2015	December 2014

Time in Guadeloupe	1 year	10 years	Several years

Initial symptoms	Generalized seizure	Generalized seizure	Ischemic stroke and tonic-clonic seizuresa

Number of colloidal cysts	1	5	0

Number of vesicular cysts	1	1	0

Number of calcified cerebral cysts	3	9	30

T. solium antibodies in serum (ELISA)	Negative	Negative	Negative

T. solium antibodies in CSF (EITB)	Negative	Positive	Not done

Screening for taeniasis in index case	Negative	Negative	Negative

Screening for taeniasis in household	Negative	Negative	Negative

Treatment	Albendazole + Steroids + Valproic acid	Albendazole + Praziquantel + Steroids + Levetiracetam	Surgical removala + Albendazole + Steroids + Valproic acid

Seizure recurrence in the first 6 months after treatment	Several	Multiple episodes in the first months after tapering steroids	No recurrence


Domain	APH	PPH	Eclampsia

Initial assessment & diagnosis	Per vaginum examination (34%)	Exploring the uterus for blood clots (39%)	Weight (4%)

Swelling on body parts related to severe anemia (8%), blurred vision related to night blindness (1%)

Diagnosed eclampsia as pre eclampsia or pregnancy induced hypertension (26%)

First line management	Antibiotic (12%)	Alternate drugs mentioned:	Diazepam (5%)

Ergometrine (34%)

Iron folic acid (11%)	Misoprostol (15%)	Diazepam with MgSO4 (3%)

Misoprostol and ergometrine (<1%)	Unindicated drugs mentioned:	Antibiotics (5%)

Injection Tranexamic acid (1%),	Anti hypertensive (6%)

Antibiotics (21%)

Ironfolicacid (11%) Calcium and multivitamin (9%)

Vaginal packing (1%)

Advice	Dietary advice and regular ANC (12%)	Dietary advice and regular ANC (20%)	Regular ANC (3% )

 	Perceived APH is caused by sexual activity or lifting weight; hence advised bed rest	New born care, Early breast feeding

 	 	And Family planning (1%)


Pt nr.	Max IAP	Macroscopy	Microscopy	Outcome

1	22	Autopsy findings: Focal ischemia on serosal and mucosal side of small bowel	Mucosa of jejunum and colon almost completely disappeared	Died 2 days after admission to the ICU

7	24	Full necrosis of the sigmoid	Transmural ischemic necrosis sigmoid	Died 67 days after decompression due to bleeding complications caused by pancreatitis

8	26	Dubious signs of ischemia of terminal ileum	Segmental chronic and acute inflammation with perforation; concordant with ischemic enteritis	Died 40 days after decompression due to sepsis and MOF

9	27	Firm necrosis of the jejunum	Severe transmural ischemic enteritis	Discharge to ward 134 days after decompression

10	27	Only necrotic remains of the sigmoid colon	Transmural necrosis	Died 13 days after decompression due to sepsis and MOF

11	29	Full black necrosis of small and large intestine	Not available	Died several hours after decompression, after withdrawal of treatment

12	32	Marbled aspect of left liver lobe	Not available	Died 47 days after decompression, due to sepsis and MOF

13	32	Patchy and full ischemia of the terminal ileum; full ischemia of cecum and left colon	ischemia ileum, cecum and left colon	Discharge to ward 16 days after decompression


Parameters	Score

Acuteness of the first cry	Absent	0

Present	2

Burst rhythmicity	Absent	0

Present	2

Constancy of the crying intensity	Absent	0

Intermediate	1

Constant	2


	Part 1 (n = 104)	Part 2 (n = 56)

Breed [number (%) of cats]

Domestic shorthair cat	85 (81.6)	46 (82.1)

Maine coon	6 (5.7)	3 (5.4)

Norwegian	4 (3.8)	3 (5.4)

Oriental	3 (2.9)	2 (3.6)

Chartreux	2 (2.8)	1 (1.8)

Birman	1 (0.9)	1 (1.8)

Siamese	1 (0.9)	–

Turkish Angora Cat	1 (0.9)	–

British Shorthair	1 (0.9)	–

Gender [number (%) of cats]

Sexually intact female	–	–

Spayed female	40 (38.8)	21 (37.5)

Sexually intact male	4 (3.8)	4 (7.1)

Castrated male	60 (57.6)	31 (55.4)

Age (in years)

Mean age ± SD	7.26 ± 4.0	7.47 ± 4.3

Viral status [number (%) of cats]

Tested for feline immunodeficiency virus (FIV)	89/104 (85.4)	49/56 (87.5)

 FIV positive	12/89 (13.5)	6/49 (12.2)

 Feline leukemia virus positive	0/89 (0)	0/49 (0)

Tested for FHV	80/104 (76.8)	43/56 (76.8)

 FHV positive	14/80 (17.5)	7/43 (16.3)


Feeding Practices	Age of Introduction of Complementary Foods

<17 Weeks n (%)	≥17 Weeks n (%)

Total	395 (62.5)	237 (37.5)

Explanations given for introducing solid foods

 Baby hungry	203 (51.4)	118 (49.8)

 Baby old enough	105 (26.6)	56 (23.6)

 Poor baby weight gain	50 (12.7)	35 (14.8)

 Maternal illness	23 (5.8)	22 (9.3)

 Other reason	14 (3.5)	6 (2.5)

Type of food infant was initially given:

 Baby cereal	244 (61.7)	145 (61.2)

 Pureed or mashed fruit or vegetables	77 (19.5)	36 (15.2)

 Pureed or mashed meat or fish	33 (8.4)	12 (5.1)

 Baby food manufacturers	27 (6.8)	25 (10.5)

 Yoghurt	5 (1.3)	11 (4.6)

 Other food type	9 (2.3)	8 (3.4)

Was it difficult to introduce solid foods?

 Yes	298 (75.4)	115 (48.5)

 No	97 (24.6)	122 (51.5)

Explanations given for difficulty in introducing solid foods

 Mother uncertain about weaning	34 (8.6)	29 (12.2)

 Infant would only accept certain solids and not others	145 (36.7)	112 (47.3)

 Infant preferred drinks to food	166 (42.0)	87 (36.7)

 Infant experienced choking or vomiting	37 (9.3)	4 (1.7)

 Other reason	13 (3.4)	5 (2.1)

Infant took ≥30 min to finish a meal?

 Yes	144 (36.5)	56 (23.6)

 No	251 (63.5)	181 (76.4)

Meals a day

 1	168 (42.5)	35 (14.8)

 2	147 (37.2)	138 (58.2)

 3 or more	80 (20.3)	64 (27.0)

Was salt added to the infant’s solid food?

 Yes	123 (31.1)	143 (60.3)

 No	272 (68.9)	94 (39.7)

Was sugar added to the infant’s solid food?

 Yes	87 (22.0)	79 (33.3)

 No	308 (78.0)	158 (66.7)

Which foods did mothers avoid giving to their infants?

 Any poultry, seafood or other meat	227 (57.5)	76 (32.1)

 Eggs or other dairy products	104 (26.3)	37 (15.6)

 Vegetables (salad)	387 (98.0)	188 (79.3)

 Fruit (fresh)	338 (85.6)	201 (84.8)

 Nuts	395 (100.0)	237 (100.0)

 Honey	387 (98.0)	189 (79.7)

 Processed foods	312 (79.0)	175 (73.8)

 Chocolate or other sweets	277 (70.1)	107 (45.1)

 High salt content foods	86 (21.8)	56 (23.6)

 High sugar content foods	157 (39.7)	98 (41.4)

 High fat content foods	203 (51.4)	186 (78.5)

 Other foods	47 (11.9)	36 (15.2)

Explanations given for not giving particular foods

 The infant dislikes them	127 (32.2)	112 (47.3)

 Heath reasons (allergies/adverse reactions)	91 (23.0)	23 (9.7)

 Food was not cooked at home	47 (11.9)	41 (17.3)

 Concern about choking	89 (22.5)	33 (13.9)

 Infant is still too young	25 (6.3)	19 (8.0)

 Other reason	16 (4.1)	9 (3.8)


	Positive keywords	Negative keywords

BTE	mould, be34, map, gp, 92, audio, inf, be52, ref, staff, reqd, be36, contact	fta, reshel, appt, it, nn, nfa, 2001, rev, lacquer, hn, km, imp, review, 2000

ITE	fta, reshel, appt, it, nn, nfa, 2001, rev, lacquer, hn, km, imp, review, 2000, nh, vent, progress, aid, dt, taken	mould, be34, map, gp, 92, audio, inf, be52, ref, staff, reqd, be36, contact, tri, n, order


A. Regions from first iteration analyses

Degree of damage to each ROI	Analysis with Fuzzy images	Analysis with Binary images

Group	Temporal ROI	Frontal ROI	n	Impaired	Not impaired	n	Impaired	Not impaired

Frontal (1)	≤ 25%	≥ 75%	68	18	50	77	19	58

Temporal (2)	≥ 75%	≤ 25%	23	10	13	25	11	14

Both (3)	≥ 75%	≥ 75%	71	48	23	63	45	18

Partial (4)	74%−26%	74%−26%	70	13	57	50	13	37

Neither (5)	≤ 25%	≤ 25%	127	9	118	144	10	134

B. Regions from second iteration analyses

	Analysis with Fuzzy images	Analysis with Binary images

Degree of damage of Putamen ROI	n	Impaired	Not Impaired	n	Impaired	Not Impaired

Putamen damaged (> 25%)	13	3	10	26	5	21

Putamen preserved (≤ 25%)	114	6	108	118	5	113


	+	−

NEURAL ACTIVITY

Spontaneous activity

 Electro-physiology	Basta and Ernst (90), Jastreboff and Sasaki (87), and Manabe et al. (91)	Ma et al. (92)

 Metabolicmarkers	Paul et al. (93)	Wallhausser-Franke et al. (94)

Burst firing	Chen and Jastreboff (88)

Auditory-evoked activity	Ma et al. (92) and Sun et al. (95)

NEUROTRANSMISSION

Excitation

 NMDA	Hu et al. (96) and Hwang et al. (97, 98)

Inhibition

 GABAA	Bauer et al. (99) (GABAA affinity)	Bauer et al. (99) (GABAA binding sites) and Zou and Shang (100)

 GAD65	Bauer et al. (99)

 GAD67		Zou and Shang (100)

 GlyR		Lu et al. (102)

 Serotonin	Liu et al. (101)	Wang et al. (103)

GENE EXPRESSION

 Arg3.1/arc		Hu et al. (96)

 Egr-1		Hu et al. (96)

 c-FOS	Wu et al. (104)	Mahlke and Wallhausser-Franke (105)

INFLAMMATORY MARKERS

 COX-2		Hwang et al. (97)

 IL1β	Hwang et al. (98, 106)

 TNFα	Hwang et al. (98, 106)


	N = 134	(%)

Food reactions

Gastro-intestinal symptoms	67	(50)

OAS – Oral Allergy Syndrome	63	(47)

Difficulty breathing	53	(40)

Skin symptoms	50	(37)

Anaphylaxis	20	(15)

Eye-nose symptoms	19	(14)

Food reactions during the last 12 months	60	(45)

Allergic diseases	100	(75)

Rhino conjunctivitis	69	(52)

Eczema	64	(48)

Asthma	44	(33)

Additional allergy/hypersensitivity	95	(71)

Additional family member with food hypersensitivity	78	(58)

Parent(s)	49	(37)

Sibling(s)	45	(34)


	Number of airlines

Pre-boarding arrangements

• Request a food “buffer zone”	5

• No “buffer zone”	3

• Request “allergen-free meal”	1

• Pre-boarding to wipe down seats and table trays	Yes 4

No 1

• Buffer zone for fragrance sensitivity	2

• Announcements to inform customers there is a peanut or tree-nut allergic passenger on board or that peanut products will not be served	Yes 4

No 7

Free snack policy on peanut/nut/sesame

• Serving peanuts	Yes 2

No 11

• Serving nuts and sesameaw	Yes 8

No 1

• First class warmed nuts	3

Gluten-free meals	Yes 11

No 1

Lactose-free meals	1

Shellfish served	Yes 4

No 3

Fish served	Yes 6

No 1

Buffer zones for passengers allergic to pets	5


Risk category	Criteria	Age to commence screening	Screening Test	Screening frequency (years)

Average-risk(Age-only)	Age 50–74 years	50	FOBT	2

Sigmoidoscopy	5

Colonoscopy	10

Moderate-risk(FamilyHx)	Family history of CRC in 1 first-degree relative ≥60 years	40	FOBT	2

Sigmoidoscopy	5

Colonoscopy	10

	Family history of CRC in 1 first-degree relative < 60 years	40b	Colonoscopy	5

Family history of CRC in 2 or more relatives

High-risk (PersonalHx)	Personal history of a bowel conditionc	40d	Colonoscopy	5

Highest-risk (Family/PersonalHx)	Personal history of a bowel condition and family history of CRC


Targeted Gene	Primer	Sequence (5′–3′)

ALDOA	Forward	ATGCCCTACCAATATCCAGC

Reverse	GACAGCCCATCCAACCCT

CDC20	Forward	GGCACCAGTGATCGACACATTCGCAT

Reverse	GCCATAGCCTCAGGGTCTCATCTGCT

CCNB2	Forward	GCGTTGGCATTATGGATCG

Reverse	TCTTCCGGGAAACTGGCTG

CDC45	Forward	TGGACTGCACACGGATCT

Reverse	AACCTGGCTGCGGTATAG

TK1	Forward	TGGCTGTCATAGGCATCGAC

Reverse	CCAGTGCAGCCACAATTACG

β-Actin	Forward	AGCGAGCATCCCCCAAAGTT

Reverse	GGGCACGAAGGCTCATCATT


Resistance pattern to the NARMS antimicrobial panel	% of isolates with resistance profile (no.)	Plasmid profile groups detected (no.)a	Species of isolates with plasmids (no.)	PFGE patterns

STR, FIS, TET, SXT	33% (14)	II, X(3), VIII	S. sonnei (4), S. flexneri	III, V, VI, IX, X

AMP, STR, FIS, TET, SXT	14% (6)	II(4), VI	S. sonnei (5)	I, IV, VII, VIII, XI, XII

AMP, CHL, STR, FIS, TET	10% (4)	none	none

AMP, CHL, TET	7% (3)	VII	S. flexneri 3a	XX, XXIII, XV

AMP, CHL, STR, FIS, TET, SXT	7% (3)	IV(2), V	S. flexneri 3a (2), S. sonnei

TET	5% (2)	I, IV	S. flexneri 1b (2)	XIX

AMP, CHL, FIS, TET	5% (2)	IV(2)	S. flexneri 2a (2)	XVII

CHL, STR, FIS, TET, SXT	5% (2)	V(2)	S. flexneri 1c (2)	XV

AMP, CHL, FIS, TET, SXT	2% (1)	IV	S. flexneri 2a	XVIII

AMP, KAN, STR, FIS	2% (1)	IV	S. sonnei	XIII

CHL, FIS, TET, SXT	2% (1)	III	S. flexneri Y var.	XXIV

AMP, CHL, STR, TET	2% (1)	IX	S. flexneri 1b	XIV

AMP, STR, FIS, SXT	2% (1)	IX	S. sonnei

AMC, AMP, GEN, STR, FIS	2% (1)	IV	S. flexneri


	Putative fox feces	Locations

	Number of samples	Positive samples (%)	Number of locations	Positive locations (%)

Anatolia	186	7 (3.8)	59	3 (5.1)

Thrace	219	1 (0.5)	114	1 (0.9)

Total	405	8 (1.9)	173	4 (2.3)


	Early differentiation	Intermediate differentiation	Terminal differentiation

Phenotypic markers

CD28	++	+/−	–

CD27	++	+/−	–

CD45RA	++	+/−	+/−

CCR7	++	+	–

CD62L	++	+	–

CD57	–	+/−	++

KLRG1	–	+/−	++

Other NKR (KIR, NKG2, and CD56)	–	+/−	++

Functional features

Proliferation	++	+	–

Telomerase activity	++	+	–

Telomeres	+++	++	+

Cytotoxicity	–	+	++

Cytokine secretion (TNF-α, IFN-γ)	–	+	++

Signaling pathways

TCR signaling	+	++	+/−

IL-2 signaling	+	++	+/−

Pi3K–AKT–mTOR signaling	+	++	+/−

p38MAPK activation	–	–	+


Amendment	Concentration	mNa	Effectiveness

Aldrich Humic Acid	1 mg C L-1	0.7(0)	LS

5 mg C L-1	0.3(6)	LS

10 mg C L-1	0.3(7)	LS

IHSS Humic Acid	1 mg C L-1	0.8(4)	LS

5 mg C L-1	0.1(7)	LS

10 mg C L-1	0.1(9)	LS

IHSS Fulvic Acid	1 mg C L-1	0.7(7)	LS

5 mg C L-1	0.1(9)	LS

10 mg C L-1	0.1(7)	LS

MCC water	∼ 5 mg C L-1*	<0.1	NR

SR lake water	∼ 10 mg C L-1*	0.8(6)	LS


Chromosome	AntiSMASH	SMURF	Unique NP

I	1	1	1

II	3	1	4

III	4	4	5

IV	3	1	4

V	6	6	7

VI	8	6	8

VII	7	6	7

Total	32	25	36


	n (%)

Primary clinical composite diagnoses

 Anterior cruciate ligament injury	8 (5)

 Meniscal injury	36 (20)

 Patellofemoral Pain Syndrome	45 (25)

 Osteoarthritis	79 (44)

 Other knee diagnoses	11 (6)

Imaging findings and diagnoses

 Osteoarthritis	96 (56)

K-L Grade 1	14 (15)

K-L Grade 2	36 (38)

K-L Grade 3	19 (20)

K-L Grade 4	13 (14)

 Meniscal tears (n)	54 (32)

Medial meniscus	49 (91)

Lateral meniscus	8 (15)

 Anterior cruciate ligament tears	16 (9)

Complete	6 (37)

Partial	8 (50)

Unclear	2 (13)

 Posterior cruciate ligament tear	1 (1)

 Soleus tear	1 (1)

 Hamstring tendinopathy	2 (1)

 Medial collateral ligament tear	1 (1)